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CHAPTER 1
INTRODUCTION
I.

Dementia
Dementia affects approximately 35.6 million people in the world (33). This

disease is a result of damaged brain cells and/or the damage of the connections
between them. It results in a decline of memory and has been determined to be caused
by other diseases or conditions ranging from severe head trauma to specific vitamin
deficiencies. To be classified as dementia, the decrease in memory must be beyond the
memory loss related to the normal ageing process and also severe enough to affect the
individuals’ daily activities. In addition, an individual with dementia experiences either a
decline in the ability to speak or understand language, recognize or identify objects,
complete motor activities, or problem solve and make accurate judgment calls. Due to
dementia possibly being caused by another disease or condition, it is important for a
physician to determine the cause of it early on. Early detection would allow the patients
to receive treatment for their condition, sometimes leading to the reversal of their
symptoms. Treatable conditions associated with dementia include delirium, depression,
drug interactions, alcoholism, specific vitamin deficiencies, and thyroid complications. If
an individual does not express any of these treatable conditions, the specific type of
dementia needs to be determined in order for it to be treated properly. Some individuals
may even express multiple types of dementia at one time making treatment more
complex (29).
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II.

Alzheimer’s disease
Alzheimer’s disease (AD) is a very progressive type of dementia. Within the

United States, it has been determined to be the 6th leading cause of death within all age
groups, and the 5th leading cause of death in those above the age of 65. AD is a disease
that was discovered over 100 years ago; however, the pursuit for the discovery of a
treatment did not become urgent until recently. With the baby boomer generation
currently aging, approximately 10 million individuals will soon be added to the older,
most at risk, population. This increase in the older population is evident when looking at
the number of deaths associated with AD. There has been a 66% increase in AD
associated deaths between the years 2000 and 2008 (29). Unfortunately, this number is
only expected to continue to increase over time.
Every 69 seconds someone within the United States develops this disease and
the outlook doesn’t look promising. By 2050 the rise in occurrence of AD is expected to
increase to the point at which someone is diagnosed with this debilitating disease every
33 seconds, rather then every 69 seconds. In the year 2011, 5.4 million Americans were
considered to have AD. Not only does the diagnosis of AD alter lives, but 61% of the
individuals with AD who are 70 years of age are estimated to die before the age of 80.
With 13% of the population over the age of 65 and 43% of those aged 85 years of age or
older developing AD, the understanding and treatment of this disease is critical for the
ever growing older population (29).
1. Signs and Symptoms of AD
Although some individuals are never diagnosed with AD due to their idea that
their symptoms are contributable to the normal aging process, the symptoms of AD are
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very prominent and debilitating. The first and most commonly recognized symptom
occurs when an individual has difficulty remembering new information. This symptom is
the result of the first stages of neuronal cell death occurring in the region of the brain
involved in forming new memories. As AD progresses and more brain cells begin to die,
the damage spreads into other regions of the brain and the individuals symptoms
worsen. Other recognizable symptoms of AD consists of confusion with orientation of
time and place, trouble speaking and writing, difficulty solving problems, memory loss,
misplacing of objects, alterations in mood and personality such as becoming withdrawn,
and altered judgment. As symptoms worsen and become more frequent, their daily life
becomes disrupted. Activities that require cognitive and functional abilities, such as
making a cup of coffee, may become too difficult for the individual to complete alone
(29).
The progression of this disease varies from individual to individual and can rate
from moderate to severe. When AD reaches the severe state, the individual may
become bed bound, unable to communicate, and may no longer be able to recognize
their family and friends. Additional complications such as decreased ability to move
around and malnutrition attributed to swallowing disorders, makes AD patients highly
susceptible to acquiring pneumonia. For these reasons, pneumonia is the most common
cause of death in AD individuals. With this disease being extremely progressive and life
changing, a caregiver is a crucial key for the survival and health of these patients (29).
2. Care Giving
For most individuals with AD, approximately 70% are taken care of by their family
members during the early stages of their disease. In 2010, approximately 14.9 million
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unpaid family members and friends provided 17 billion hours of care to their loved ones
with AD. If these individuals were to be paid, it would have totaled over $202 billion
dollars. Despite not being paid for the care they provide, they also experience emotional,
physical, financial, and work related stress. This stress increases when the AD patient
has additional health issues. This situation is very common and became evident in 2004
when 26% of AD patients over the age of 65 who received Medicare beneficiaries were
also diagnosed with coronary heart disease, 23% with diabetes, 16% with congestive
heart failure, 13% with cancer, and 8% with Parkinson’s disease (29).
When the patient’s status becomes severe, around the clock care is usually
needed. The most common solution is to place the individual in a nursing home. By the
end of the year 2011, the healthcare, housing, and hospice services cost the United
States approximately $183 billion. This total was calculated without including the cost of
family members and caregivers who are unpaid. With the incidence of AD increasing,
this number is expected to rise to $1.1 trillion in the year 2050 (29). These statistics
show not only the emotional impact on society, but also the financial impact.
3. Types of AD
Individuals can fall into one of two categories; familial AD (FAD) or non-familial
AD. FAD occurs in less then 1% of the population and has been discovered to develop
due to rare genetic mutations. When an individual inherits a mutation on chromosome
21, the gene for the amyloid precursor protein, chromosome 14, the gene for the
presenilin 1 protein, or on chromosome 1, which is the gene for the presenilin 2 proteins,
it guarantees that they will develop AD. Some individuals with FAD can begin developing
their symptoms as early as 30 years of age. Individuals without these genetic mutations
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are said to have non-familial AD. This category can be further divided into two sub
categories; late-onset AD and early-onset AD. When non-familial AD occurs in people
under the age of 65, it is classified as early-onset. When an individual develops AD at or
above the age of 65 it is considered to be late-onset. Of the two non-familial types of AD,
late-onset is the most prevalent form (29). These types of AD are becoming better
understood; however, the etiology remains unknown making this disease difficult to
diagnose and ultimately treat (24).
4. Diagnosis
Currently, primary care physicians are not recommended to perform any
assessment tests for AD on their patients unless the individual is presently displaying
signs and symptoms. The pathway to diagnosis is not well established and is usually
based on the person’s history in addition to cognitive and behavioral examinations
performed by the physician (29). An individual may also undergo magnetic resonance
imaging (MRI) to possibly identify some changes in the brains physical appearance;
however, it also can provide an inaccurate diagnosis. A diagnosis can only be confirmed
after an individual has died and an autopsy of the brain can be conducted (37). Some
studies suggest that approximately 80% of individuals with AD have not been diagnosed.
The reasoning for this statistic is thought to be due to the lack of health care, or
individuals assuming symptoms are a part of their normal aging process. If a person is
diagnosed with FAD, the cause is known to be contributed to genetics; however, the
cause of non-familial AD, which is more prevalent, is not well understood. Despite not
having an accurate diagnostic tool, some risks factors for developing AD have been
established and are often considered by the physician upon diagnosis (29).
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5. Risk Factors
When an individual is being assessed by their physician, specific risk factors
which consist of modifiable and non-modifiable factors are considered. Non-modifiable
risk factors include increasing age, family history, the additional diagnosis of mild
cognitive impairment (MCI) and genetics. Increasing age is the greatest risk factor. AD is
not a part of the normal ageing process, but reaching the age of 65 greatly increases the
chances of an individual developing this disease. MCI has also been discovered to be a
risk factor for AD. It was found that 15% of those who have the condition MCI have
progressed to dementia later on. MCI is considered to possibly aid in the progression of
normal aging neuronal loss to the substantial neuronal deficits found in AD individuals
(29).
Genetics has been found to play a major role in the development of FAD;
however, it has also been discovered to act as a risk factor for non-FAD individuals.
Apolipoprotein E is a protein that carries cholesterol within the bloodstream. There are 3
forms, ε2, ε3, and ε4. Each person inherits one form of the APOE gene from each
parent. It has been found that those who inherit the APO E ε4 form have an increased
risk for developing AD when compared to those who inherit the ε2 or ε3 forms. If an
individual inherits APO E ε4 from both parents, their risk increases even more. Having
this form of APOE gene does not guarantee the occurrence of AD but it has been shown
to act as a risk factor for the development of it (29). All of these risk factors are nonmodifiable making it impossible for an individual to control the acquisition of them;
however, there are some that people can modify to help decrease their risk for
developing AD.
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Modifiable risks that can alter an individual’s chances for developing AD include
acquiring head traumas or traumatic brain injuries. When someone experiences a
moderate head trauma, their chances for developing AD doubles. A moderate head
trauma is characterized as a head injury that causes the loss of consciousness or
amnesia that lasts for more then 30 minutes. A severe head trauma is when the loss of
consciousness lasts for more then 24 hours. If this situation occurs, the individual’s
chances of acquiring AD increases by 4.5 times (29).
Additional modifiable risks include high cholesterol, type 2 diabetes, high blood
pressure, a sedentary lifestyle, smoking and obesity; also referred to as cardiovascular
risk factors. These risks are associated with the development of AD risks due to the idea
that the heart ensures the brain receives enough oxygen and nutrient enriched blood in
order for it to function normally (29). Without a healthy heart, the brain will not receive
what it needs and may result in the decline of the brains functionality. If a person avoids
head traumas and takes care of their heart, their chances for developing AD have been
shown to decrease.
Other factors have also been researched to determine if they play a role in the
development of AD. These factors include race, gender, and socioeconomic status. In
2011, two thirds of the 5.2 million individuals diagnosed with non-familial AD were
women. Despite this statistic, it can not be determined that women are more likely then
men to develop AD. It can not be stated due to women living longer then men and this
possibly affecting this statistic; however, it is a startling statistic that should be looked at
further. Another factor considered is the socioeconomic status of an individual. It is
thought that an individual with a lower socioeconomic status has a higher risk of
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developing AD. This may be due to their lack of achieving a higher education and their
inability to obtain adequate health care. Education may play a direct role because
research has shown that learning allows your brain to grow which in return increases the
number of neuronal synapses. Since AD decreases the number of neuronal synapses,
the more you have to begin with may possibly delay the acquisition of the debilitating
symptoms. Race was also looked at as another risk factor and was in fact determined to
play a role in the risk for developing AD. It was discovered that African Americans are
twice as likely then Caucasians to develop AD. Hispanics also have a higher risk then
Caucasians and are approximately 1.5 times more likely to develop it. These differences
are most likely due to the physiological variations among races (29). With the risks for
the development of AD coming in from so many different angles, an individual should
modify the risks they can and also be aware of those they can not.
6. Treatments
With the large number of risks and the increasing prevalence of AD, a treatment
solution is necessary. Currently, two drugs, cholinesterase inhibitors and Namenda, are
being prescribed to AD patients. These treatments do not prevent or cure this disease;
however, they have been shown to delay the progression or onset of it. Cholinesterase
inhibitors prevent the breakdown of acetylcholine which has been found to be important
for memory and learning. The exact mechanism of acetylcholine and the effects it has on
AD is not well known but it has been found to be effective for the prevention of
symptoms from worsening. Namenda, N-methyl-D-aspartate antagonist, regulates the
amount of glutamate within the brain. When glutamate levels are above the normal
range, neuronal cell death has been shown to occur. Preventing the accumulation of
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glutamate has been shown to be important for allowing patients to carry out their daily
activities for an extended period of time (31).
Despite the benefits from these drugs, there are also negative side effects. In
order to try and prevent them, individuals begin taking these drugs at low dosages and
then slowly increase them over a period of time. The side effects can include nausea,
vomiting, diarrhea, weight loss, loss of appetite, and muscle weakness while taking
cholinesterase inhibitors. Side effects for Namenda include dizziness, headaches,
constipation, and confusion. Due to these drugs effecting different chemicals and
pathways in the body, it is possible for the patient to receive both of them at the same
time (31). Although it is a step in the right direction, only half of the individuals receiving
these drugs actually end up benefiting from them. Unfortunately, if an individual does
benefit from taking them, it usually only delays their symptoms for approximately 6 to 12
months (29). To develop a more effective treatment, the causes and hallmarks of AD
need to be better understood.
7. Hallmarks of AD
Although some of the risks and symptoms of AD have been discovered, the real
mechanisms that are known to be the hallmarks of this disease need to be better
understood. There are two definitive characteristics of AD; senile plaques and
intracellular neurofibrillary tangles (24). A normal adult brain contains approximately 100
billion neurons. Each neuron contains branching extensions referred to as dendrites
which allow them to form over 100 trillion connections with other neurons known as
synapses. These connections are vital for the brain to function and allow the neurons to
pass information such as memories, thoughts, sensations, emotions, skills, and
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movements amongst one another. In the brain of an individual with AD, the number of
neuronal cells and synapses begin to cease due to the accumulation of senile plaques
and the formation of neurofibrillary tangles (29).
a. Tau Proteins
One known hallmark of AD is the intracellular accumulation of neurofibrillary
tangles. Microtubule-associated proteins, also known as tau proteins, help to stabilize
and promote the assembly of microtubules for neuronal cells within the normal brain
(24). In an AD brain, tau proteins become hyperphosphorylated which in turn causes
them to no longer function and begin to accumulate. As the number of
hyperphosphorylated tau proteins build up, they eventually create neurofibrillary tangles.
Due to these tangles forming amongst the neuronal cells, they begin to cause
irregularities in axonal transport ultimately resulting in the prevention of the
transportation of vital nutrients and chemicals (5, 29). In the end, the inability to receive
these important chemicals leads to cell death and results in the progression of AD (24).
b. Senile plaques
Senile plaques, also known as amyloid beta (Aβ) plaques, build up in the
damaged axons of the neurofibrillary tangles and are another hallmark for AD (37). The
amyloid precursor protein (APP) is approximately 120kDa in size and is expressed in
mammalian cells (7). It is a vital protein that mediates neurite outgrowth and when
cleaved, it produces chemicals that are important for the maintenance and formation of
neuronal synapses (37). APP is processed post-transitionally and is first cleaved on the
cells surface by α-secretase. This produces a molecule that is approximately 100kDa in
size that is usually referred to as sAPPα. It has been discovered to aid in the health and
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development of synapses. The remaining APP is then cleaved by β-secretase which
produces the N-terminal fragment referred to as sAPPβ. This fragment is internalized,
and for normal individuals, is vital for axonal pruning. For individuals with AD, the
internalization of sAPPβ causes additional neuronal cell death which aids in the
progression of their disease. The last cleavage of APP is carried out by γ-secretase.
This protease has the ability to yield two different products; Aβ1-42 and the APP
intracellular domain (AICD). The presenilin-1 (PS1) and presenilin-2 (PS2) genes play a
role in whether or not the Aβ1-42 fragment is formed. This is evident when looking at
those individuals diagnosed with FAD which have been found to have mutations on the
PS1 and PS2. The Aβ1-42 fragments have aggregate properties; therefore, they
accumulate and cause oligomerization of the fragments resulting in plaque formation.
When the plaques continue to build up, vital mechanisms such as ion channels, calcium
homeostasis, energy metabolism, and glucose metabolism becomes impaired (4).
Aβ1-42 fragments have been found in the cerebral spinal fluid of normal
individuals and can be related to the normal aging process; however, normal brains are
able to degrade some of these fragments preventing excessive accumulation (7). In
1992, J. Hardy developed the amyloid cascade hypothesis. His idea suggested that the
amount of Aβ1-42 produced in the brains of AD patients is not equal to the amount
cleared, ultimately causing the build up and accumulation of senile plaques (5). In FAD
patients, it has been noted that the genetic mutations are the cause for the
overproduction and accumulation of Aβ1-42 fragments, but unfortunately the mechanism
for non-familial AD patients still remains unclear (17). The understanding for the
overproduction of these plaques is necessary due to them playing a major role in
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neuronal cell death via lipid peroxidation, imbalance of ion homeostasis, and
programmed cell death; all of which results in the progression of AD (37).
8. Underlying Causes of AD Neurodegeneration
Based on the knowledge for the hallmarks for AD it may seem clear as to which
issues need to be to addressed in order to slow the progression of or even cure the
disease; however, it is unfortunately not that simple. The formations of neurofibrillary
tangles and Aβ plaques have been found to lead to the development of additional
underlying causes of neurodegeneration (4). Two well known underlying causes are
oxidative stress and inflammation. These characteristics can aid in the progression of
AD eventually becoming detrimental to the individual. Reactive oxygen species
formation and microglial activation have been found to play key roles in the development
of these underlying causes of AD neurodegeneration (26).
a. Reactive Oxygen Species
Reactive oxygen species (ROS) carry an extra oxygen molecule making them
highly reactive chemicals (3). They are formed as a byproduct of aerobic respiration
carried out by mitochondria within the cell. In a normal cell, the high reactivity of ROS is
balanced out by antioxidants and enzymes. For an individual with chronic diseases such
as AD, ROS is produced in excessive amounts. As a result, the body can not balance
out the disproportionate amounts causing highly reactive ROS chemicals to remain
present (6). The formation of these chemicals not only aids in the development of the
hallmarks of AD but is also linked to oxidative stress and inflammation.
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ROS formation has been found to play a key role in the formation of tau proteins.
When there is an increase in ROS formation it in turn activates kinases such as protein
kinase C (PKC), protein kinase A (PKA), and extracellular signal-regulated protein
kinase 2 (Erk2). In the normal brain, these kinases are not activated; therefore, their
activation in the AD brain is considered to cause the irregularity or hyperphosphorylation
of the tau proteins. Tau then becomes disassociated from the microtubule causing
oligomerization of the Tau and destabilization of the microtubule. As a result,
neurofibrillary tangles form intracellularly and neuronal cell apoptosis occurs (4).
The other hallmark of AD, Aβ plaque formation, has also been linked to ROS
formation. ROS is thought to be produced as a result of the accumulation of Aβ1-42
fragments. As Aβ plaques form, ROS formation becomes over expressed. This excess
formation of ROS leads to oxidative stress, membrane damage, and ultimately further
neuronal apoptosis. Also, the ROS formed by Aβ plaques can in turn be used for
additional hyperphosphorylation of tau proteins (4).
Oxidative stress and inflammation are additional consequences from increased
ROS formation (4). It has been found that mitochondrial ROS can act as signaling
molecules and activate pro-inflammatory agents (6). The shift in the balance of ROS
formation and degradation leads to oxidative stress and lipid peroxidation which has
been found to occur in the brains of AD individuals. The lipid peroxidation then causes
membrane damage and oxidative stress results in the production and activation of p53,
Bad and Bax. These three chemicals take part in cell death via apoptosis and
excitotoxicity (3). As oxidative stress increases, there is an increase in the production of
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poly (ADP-ribose) polymerase (PARP). This protein can alter many transcription factors
including one that regulates the activation of microglial (28).
b. Microglial Activation
Microglial are macrophages whose key role is to act as an immune response cell
within the central nervous system. The exact role they play in the brain is not well
known; however, their activation associated with the aging of the hippocampus and
neuropathic pain leads to neurotoxicity and over expression of inflammation (38).
Inflammation begins when bioactive lipids that are produced by arachidonic acid known
as eicosanoids are released. The most common eicosanoid released is prostaglandin E2
(PGE2) and due to its prevalence within the body during inflammation, it serves as a
mediator for cytokine-target gene expression (16). When microglial become activated,
many morphological changes occur as well as an increase in pro-inflammatory agents
such as cytokines (27).
The body begins the process of inflammation when it detects injuries from certain
stimuli such as damaged cells, pathogens, and irritants. When this process is working
normally, it is vital for the body in order for it to return it to its homeostasis. It
accomplishes this by eliminating the harmful stimuli. The problem occurs when the
body’s response causes uncontrolled inflammation. This can actually induce more harm
then good, making the regulation of inflammation important for the health of an individual
(16). In someone with AD, Aβ plaques have been shown to cause microglia activation
which then leads to cytokine production. This recruitment of the pro-inflammatory
cytokines causes inflammation to be expressed beyond normal levels causing harm to
the individual (4).
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Microglial can cause the progression of AD through another pathway was well,
the regulation of metalloproteinases (MMPs). When microglial become activated, MMPs
are released. These molecules have the ability to open the blood brain barrier. This
characteristic allows for direct neurotoxicity of the brain ultimately resulting in additional
neuronal cell death (28).
Microglial activation and ROS formation plays vital roles in neurodegeneration.
They seem to have their own direct mechanisms, but more information is needed. For
example, when examined under experimental conditions, Aβ plaques caused activation
of microglial; however, despite microglial releasing neurotoxic chemicals, they can also
release neurotrophic agents that can aid in the reduction of Aβ plaques via phagocytosis
(11). As each mechanism for the neurodegeneration of AD is discovered, many are
beginning to be linked to together taking one step closer to the discovery of a treatment.
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Figure 1: Amyloid plaque and neurofibrillary tangle formation in Alzheimer’s disease.
Source: Cell Signaling Technology (2010) Amyloid Plaque and Neurofibrillary Tangle
Formation in Alzheimer’s Disease. Cellsignal.com.
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III.

Biomarkers
Due to inflammation and oxidative stress being considered as underlying causes

of AD neurodegeneration; two biomarkers will be looked at throughout this research:
cyclooxygenase-2 (COX-2) and poly (ADP-ribose) polymerase (PARP). COX-2 will be
examined due to it being a well known marker for inflammation in non-AD and AD
individuals (37). PARP alters the transcription factor that regulates the activation of
microglial which, as stated earlier, are known to regulate pro-inflammatory agents.
These characteristics allow it to be used as an inflammation biomarker (28). Additionally,
research shows PARP becomes activated and over expressed in the presence of
oxidative stress also making it an oxidative stress marker (15). Due to the characteristics
of these biomarkers, both have been used widely in AD research.
1. Cyclooxygenase
With researchers knowing inflammation is some how linked to Aβ plaque
formation, they have recently discovered cyclooxygenase (COX) as a possible
biomarker for it in individuals with AD. COX is considered to be a biomarker due to it
being a rate-limiting enzyme that plays an important role in the production of bioactive
prostaglandins (PGs) (37). PGs, as explained previously, are synthesized from
arachidonic acid and are thought to influence the onset, magnitude, duration, and course
of the inflammation process (16). This is accomplished by two isoforms of COX, COX-1
and COX-2. These isoforms are encoded from different genes and is noticed when
looking at their amino acid sequences due to approximately 40% of their amino acid
sequences varying. Attributable to their amino acid diversity, their pathophysiological
roles differ as well. COX-1 is predominately found regulating the physiological functions
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of the kidney and a variety of tissues such as platelets. Since, COX-2 is derived from
prevalent inflammatory chemicals, PGs; it is expressed by a variety of stimuli such as
cytokines and growth factors. Due to the characteristics of the COX-2 isoform, recent
research has discovered that COX-2 may play a role in diseases such as cancer,
neuronal disorders, and those that include the characteristic of inflammation such as AD
(37).
There have been many studies that have been able to link inflammation to AD
by looking at COX-2 as an inflammatory marker. One piece of evidence that suggests a
relationship between AD and COX-2 discovered that individuals who received nonsteroidal anti-inflammatory drugs (NSAIDs) compared to those who did not, delayed the
onset and/or progression of AD (18). Most NSAIDs work by inhibiting COX causing the
link between COX and AD to be looked at more closely (2). Additionally, it was found
that the expression levels of COX-2 were higher in certain brain regions of individuals
with AD when compared to non-AD patients. COX-2 was elevated in the frontal cortex,
hippocampus, and thalamus regions of the AD brain. It was also determined that COX-1
levels were not significantly different within the hippocampus neurons between AD and
non-AD patients; therefore, specifying that the COX-2 isoform is the one most commonly
expressed (22). Further research discovered that there is a correlation between COX-2
immunoreactivity and the number of Aβ plaques present within the neurofibrillary tangles
containing damaged axons. Based on this past research Yoshimoto et al. in 2001 found
that the mRNA expression of APP was stimulated when COX-2 was overexpressed. As
a result of this increase in APP production, the amount of sAPPβ and ultimately Aβ1-42
fragment production was also stimulated (37).
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Along with clinical and cell models, animal models have also been used and
displayed similar evidence. Cąkata et. Al in 2007 injected Aβ intracerebroventricularly
into twelve month old C57Bl6 mice. For the group injected with Aβ, the levels of COX-2
expressed at the protein level increased significantly. It was determined that the COX-2
immunoreactivity was elevated due to systemic inflammation. These characteristics
coincided with behavioral changes as well. The mice injected with Aβ demonstrated an
increase in memory disturbances via a lack in object recognition when compared to the
control mice. Another group of mice also received the Aβ injection along with an
additional injection of COX-2 inhibitor. This group of mice demonstrated no memory
deficits or changes in motor skills (2). Wilcock et al. took the research one step further in
2011 by using transgenic AD mouse models. They altered specific inflammatory genes
and showed that by decreasing the expression of them, it leads to significant reductions
of Aβ fragments (34). With many researches carrying out experiments such as these, it
poses the possibility of a link between inflammation, COX-2, and the accumulation of Aβ
plaques. The observation of Aβ plaques and neurofibrillary tangles being surrounded by
active inflammatory cells has also been noted, but the mechanistically effects
inflammation has on AD remains controversial and not well understood (34).
2. Poly (ADP-ribose) polymerase (PARP)
A nuclear protein that activates the release of pro-inflammatory agents such as
cytokines, ROS, and proteases, is known as poly (ADP-ribose) polymerase (PARP).
There are many forms of this protein; however, PARP-1 accounts for over 90% of the
total PARP activity within a cell (28). It is a protein that is well known for its ability to

20

repair DNA. Due to this characteristic, it also allows it to bind to certain transcription
factors causing them to become altered (15).
The alteration of transcription factors that PARP plays a role in regulates the
release of pro-inflammatory agents. PARP can regulate the expression of many
inflammatory mediators; however, all of them are regulated by one factor; the nuclear
factor-kappa β (NF-κβ) (36). NF-κβ is known to be regulated by the binding and altering
of DNA via PARP (15). NF-κβ regulates macrophage and microglial activation (2). As
discussed earlier, microglial activation can release pro-inflammatory agents and
increase inflammation. Experimental data has shown that by knocking out the PARP
gene, in mice and cells, reduction of both the activation and transcription of NF-κβ can
be reduced, ultimately leading to the reduction of pro-inflammatory agents (36).
With PARP linked to inflammation, it has become looked at more carefully in AD
research. Experimental data has discovered that within the brains of AD individuals,
PARP is over expressed and highly active (11). The reasoning for this is thought to be
due to PARP becoming activated by single strand breaks within the DNA possibly due to
oxidative damage (36). Widespread over activation causes cells to become depleted of
intracellular NAD+ and ATP pools ultimately leading to cell death (15, 36). This occurs
due to PARP initiating the cycle of transferring ADP ribose units from NAD+ to a nuclear
protein resulting in the consumption of the cells energy (36). This is problematic in AD
individuals due to the accumulation of Aβ plaques causing an increase in oxidative
stress leading to additional DNA damage and the over expression of PARP (15).
With the characteristics of PARP and ROS formation causing an increase in
oxidative stress and inflammation, AD individuals face a constant battle. Based on
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previous research, the Aβ plaques formed in AD individuals causes an increase in ROS
formation. This can then lead to inflammation, oxidative stress, and an increase in tau
protein hyperphosphorylation. Oxidative stress causes an over activation of PARP which
in turn causes activation of microglial. Due to the microglial activation, additional proinflammatory agents are released and additional Aβ plaques are formed. The constant
cycle between over expression of inflammation and oxidative stress makes the treatment
of AD very difficult.
Due to ROS formation playing a key role in the neurodegeneration of AD
individuals, antioxidants can potentially aid in the delay of AD progression. The high
reactivity of ROS and imbalance in degradation and formation, leads to the underlying
causes of AD neurodegeneration. With more antioxidants present it may be able to
balance out the reactivity of ROS and reduce the amount of reactive ROS within the
cells. By examining biomarkers such as PARP and COX-2, their expression may be able
to be decreased by the use of antioxidants, such as oil palm phenolics.
IV.

Oil Palm
Oil palm belongs to the species Elaeis guineensis and originates from the tropical

forests in West Africa. Due to an increase in industrial cultivation of this species, other
countries such as Malaysia and Indonesia are becoming large producers (30). Palm oil
has a fatty acid composition of a 1:1 ratio of saturated to unsaturated fatty acids; this
makes the oil semi-solid at room temperature. Due to this characteristic, margarine and
shortening can be produced without hydrogenation, making it the second largest
consumed oil in the world (27). Oil palm contains two separate components; fat-soluble
compounds as well as large amounts of water-soluble phenolic compounds.
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1. Fat Soluble Components
As oil palms popularity increases among consumers and researchers,
components of it are beginning to be looked at more closely. Research has shown that
individuals who are consuming palm oil as a part of a low-fat diet can better maintain
their plasma cholesterol and lipoprotein cholesterol at more desirable levels (27). The
fat-soluble components include vitamin E (30% tocophorels, and 70% tocotrienols) and
carotenoids (23, 27). During the processing of palm oil, the carotenoids are usually
removed and the levels of tocotrienols are highly reduced. This is due to the use of high
temperature steam deodorizations. It has been shown that compounds within the fatsoluble components have anti-cancer properties so it is important to try and preserve
these nutrients (27). With the fat-soluble components retaining health benefits, the
water-soluble compounds are now being used in current research as well.
2. Water Soluble Components
Oil palm phenolics (OPP) consist of the water-soluble compounds retained after
extraction of palm oil from the oil palm fruit (27). These constituents are extracted from
oil palm by vigorous centrifugation and membrane filtrations (23). Current technology
allows the extraction of OPP to maintain its vital compounds by using separation
techniques that isolate each compound based on its molecular weight (27). OPP
consists of three major phenolic acids, caffeoylshikimic acid isomers, protocatechuic
acid and p-hydroxybenzoic acid. It has shown to not cause toxicity within various animal
models; therefore, it has become a component in many upcoming research experiments
including this one (23).
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Phenolics have high antioxidant capacities due to their aromatic ring structure
containing a high reduction-oxidation potential. This characteristic allows them to act as
hydrogen donors, reducing agents, singlet oxygen quenchers and metal chelators.
Antioxidants prevent the formation of prooxidants by scavenging for them or by inducing
their decomposition. This is helpful due to prooxidants being linked to the triggering of
chronic diseases and ageing via oxidization of macromolecules. This is carried out by
hydroxyl radicals causing lipid peroxidation which in turn modifies DNA bases or
damages proteins resulting in tissue damage. Prooxidants are also linked to
inflammation due to their capability to regulate gene expression specifically the nuclear
factor kappa-B and activator protein-1 (23).
OPP works as an anti-oxidant via alteration of genes by either silencing them or
turning them on. It has been determined that OPP effects gene expression in the heart,
liver and spleen (23). These changes in gene expressions were not drastic enough to
cause harm or alterations to the organs or hematology; however, it did alter them
enough to up-regulate lipid catabolism and down-regulate cholesterol biosynthesis in the
liver (23). OPP also promoted aggregation of platelets in the spleen and slowed the
ageing process in hearts. Due to prooxidants playing an important role in the link
between oxidative stress and inflammation for the onset of chronic diseases, phenolics
such as OPP have been shown to contain many possible therapeutic elements (23).
V.

Hypothesis
The high number of reports linking inflammation and oxidative stress to Aβ

plaques formation has opened the door to possibly using naturally occurring antioxidants
such as OPP to decrease inflammation and ultimately retard the accumulation of Aβ
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plaques. This information is a small step that will hopefully lead to the better
understanding of AD and eventually the prevention and/or treatment of it. Thus, it was
hypothesized that the addition of oil palm phenolics will decrease inflammation and
oxidative stress in familial Alzheimer’s disease cells in vitro. To test this hypothesis, the
specific aims stated below were carried out:
Specific Aim I: To determine the anti-amyloidogenic activities of OPP, if any, by
measuring the inhibition of formation and destabilization of amyloid beta proteins using a
thioflavin T (ThT) binding assay.
Specific Aim II:
II (a): To determine the effect of OPP on cell growth and viability of the FADmutant cell constructs with increase in passage using MTS assay.
II (b): To investigate the effects of OPP on the protein expression of APP, COX-2
and PARP, known biomarkers for AD and inflammation in FAD mutant and WT
cells.
Specific Aim III: To investigate the effect of OPP on the mRNA expression of COX-2
and amyloid precursor protein (APP) in FAD mutant and WT cells using real time RTPCR.
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CHAPTER 2
METHODOLOGY
Specific Aim I: To determine the anti-amyloidogenic activities of OPP, if any, by
measuring the inhibition of formation and destabilization of amyloid beta proteins using a
thioflavin T (ThT) binding assay.
1. Preparation of Amyloid Beta Fibrils
For both the destabilization and deformation assays, the Aβ 1-42 proteins
(Peptides Internationals, Louisville, KY) needed to first be dissolved and diluted to the
concentrations described by Katayama, S., Ogawa, H., and S. Nakamura in 2011 (10).
This was accomplished by dissolving 0.5 mg of Aβ 1-42 proteins in 400 ul of a 0.1%
ammonia solution for a final concentration of 250 uM. It was then divided equally into 4
vials, sealed, and stored at – 80 degrees Celsius until use. Using a 50 mM phosphate
buffer containing 100 mM of NaCl and with a final pH of 7.5, the 250 uM Aβ 1-42 protein
solution was diluted to a final concentration of 25 uM. For the destabilization experiment,
the 25 uM Aβ 1-42 protein solution was incubated at 37 degrees Celsius for 24 hours in
order to allow the amyloid beta fibrils to form. The inhibition of formation assay was
carried out by adding the OPP concentration of 300 ul/10 ml directly to the 25 uM Aβ 142 protein solution and incubating it for 24 hours at 37 degrees Celsius.
The OPP concentration used in this experiment was 300 ul/10 ml. This
concentration was used based on the results of the MTS assay showing that it was
statistically significant when compared to the sample control. When the 25 uM Aβ 1-42
protein solution was created, each vial contained a total volume of 100 ul without OPP.
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In order to achieve this desired concentration, 3 ul of OPP was added to the 100 ul of
the 25 uM Aβ 1-42 protein solution.
Once the 24 hour incubation period was over, the OPP concentration of 300
ul/10 ml was added to the destabilization vials. Each vial, for both the destabilization and
formation inhibition assay, was then vortexed and placed in a dark area. Thioflavin T
(ThT) is a light sensitive fluorescence marker; therefore, the mixing and loading of this
solution was done in a dark space. 1.2 ml of ThT solution containing 50 mM glycine,
NaOH buffer with a final pH of 8.5 and a final concentration of 5 uM was added to 6 ul of
each sample for both assays. Each tube was then vortexed and loaded into a black 96
well microtitier plate, in triplicates, with 250 ul of volume in each well. Multiple controls
were also prepared and added to the microtiter plate. A ThT control was made by adding
6 ul of ethanol to 1.2 ml of ThT solution. A sample control was used to detect amyloid
fibril formation without OPP and was created by adding 6 ul of 25 uM Aβ 1-42 protein
solution to 1.2 ml of the ThT solution. Lastly, an OPP buffer control was prepared by
adding 6 ul of OPP to 1.2 ml of the ThT solution. This was done in order to ensure the
fluorescence readings were due to the ThT binding to the hydrophobic grooves of the βsheet surface of the amyloid beta fibrils rather then the OPP itself creating fluorescence.
Once all samples and controls were loaded into the microtiter plate, it was covered with
aluminum foil in order to help prevent light from altering the samples.
2. Spectrofluorometer
After the samples were prepared and loaded onto a 96 well microtiter plate, it
was then read using a Tecan GENios Microplate Reader (MTX Lab Systems Inc.,
Vienna, VA). The wavelengths were set at 450 nm for excitation and 492 nm for
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emission. Shaking was turned on and the assay was conducted at room temperature.
Each sample was read every 30 minutes for a total time period of 24 hours.
3. Statistical Analysis
Once all the readings were recorded, the OPP 300 ul/10 ml sample fluorescence
was determined by averaging the three readings and subtracting the fluorescence
averages of the OPP buffer fluorescence and ThT control. The sample control
fluorescence readings were calculated by averaging the three readings and subtracting
the average ThT control fluorescence. The OPP buffer control was not subtracted from
the sample control due to no OPP being present. The sample control and OPP 300 ul/10
ml sample readings were then divided by the starting fluorescence value for the OPP
300 ul/10 ml sample. This was done in order to make all the values relative to 1. The
change in fluorescence over a 12 hour time period was then graphed to illustrate the
overall decrease in ThT fluorescence which is relative to the decrease in the number of
Aβ plaques.
Specific Aim II (a): To determine the effect of OPP on cell growth and viability of the
FAD-mutant cell constructs with increase in passage using MTS assay.
1. Cell Lines
The cell lines were kindly provided by Dr. Yilong Shu from the University of
Alabama with permission of release from Dr. Lennart Mucke from the Gladstone Institute
of Neurological Disease located at the University of California, where they were
constructed. B103, rat neuroblastoma cells, were transfected with cDNA constructs. The
FAD cells were constructed by the insertion of a mutant cDNA construct,
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hAPP695mutant, in order to over express APP levels. The wild type cells also received a
cDNA construct, hAPP695wt, and were inserted to express APP at levels found in nonAD individuals in order to be used as a control. These constructs were confirmed to be
stably transfected within the cell lines via Western blot analysis (19).
2. Passage Experiment
Since a rat neuroblastoma cell line was used, it was important to determine at
what passage the cells would begin to lose their construct. This was vital information in
order to know at which point the cells could no longer be used in experiments due to the
loss of their AD-like characteristics. Cells are considered to undergo one passage each
time trypsin/EDTA is added to detach the cells from the flasks wall. When the cells were
received from Dr. Yilong Shu’s lab they were in the first passage. Once the cells were
thawed and enough were grown in order to conduct an experiment, they were in the third
passage.
a. Re-Seeding of Cells
This experiment was initiated by thawing one vial of WT cells and one vial of FAD
cells received from Dr. Yilong Shu, and seeding them for growth. The cells received
were frozen within dimethyl sulfoxide (DMSO); therefore, they were thawed in a water
bath maintained at 37 degrees Celsius and then titrated. The contents of the FAD vial
were transferred into 13 ml of selection media in a T75 flask. The WT vial contents were
placed into a separate T75 flask also containing 13 ml of selection media. The selection
media was composed of 410 ml of 1X DMEM (Dulbecco’s Modified Eagle Medium)
(Cellgro, Manassas, VA), 50 ml of fetal bovine serum (FBS) (Gibco, Carlsbad, CA), 25
ml

off

horse

serum

(heat

inactivated)

(Gibco,

Carlsbad,

CA),

5

ml

of
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penicillin/streptomycin (Gibco, Carlsbad, CA), 5 ml of L-glutamine 100X (Gibco,
Carlsbad, CA), and 5 ml of G418 (geneticin) (Gibco, Carlsbad, CA). This composition
was optimized by Dr. Lennart Mucke’s lab. The T75 flasks containing the cells were then
placed into an incubator maintained at 37 degrees Celsius, with 5% carbon dioxide and
95% humidity (19). The selection media was removed from the flask and replaced with
13 ml of fresh selection media the following day in order to remove any DMSO.
Both FAD and WT flasks were viewed under a microscope and left to grow until
they were approximately 90% confluent. Once confluent, the selection media was
removed from the flask, cells were washed with 10 ml of 10X phosphate buffer saline
(PBS) (Cellgro, Manassas, VA), and 1 ml of 1x trypsin/EDTA (TE) (Cellgro, Manassas,
VA) was added. Any cells that were floating within the selection media were considered
to have lost the cDNA construct and were removed when the cells were washed with
PBS. After approximately 5 minutes of letting the flasks sit with TE, 9 ml of selection
media was added to wash the cells from the flasks wall and to inactivate the TE. All
contents were removed from the T75 flask and placed into a 15 ml centrifuge tube. The
cells were centrifuged for 3 minutes at approximately 1,500 RPM. A pellet formed and
the supernatant was removed. 1 ml of selection media was added and titrated to
completely dissolve the pellet. 0.5 ml was placed into a T75 flask containing 13 ml of
selection media, and the other 0.5 ml was placed into another T75 flask also containing
13 ml of selection media. This was completed with both the FAD and WT cells
separately. The T75 flasks were placed in the incubator with the same parameters
stated earlier and monitored until they were again approximately 90% confluent.
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b. Counting and Freezing Cells
For each passage of WT and FAD cells, one T75 flask was frozen and the other
was counted and then re-seeded as shown in figure 2. Once the cells became confluent,
the T75 flasks were prepared as though they were going to be re-seeded following the
same procedure stated earlier in section (a). Once the pellets were formed after
centrifuging, one was frozen while the other was counted and then used to re-seed.
To count the cells, the pellet was re-dissolved in 1 ml of selection media followed
by the addition of 9 ml of selection media. The 15 ml centrifuge tube was inverted to mix,
and then 15 ul was aliquoted into a 1 ml centrifuge tube. 15 ul of trypan blue (Sigma
Aldrich, Saint Louis, MO) was added and was thoroughly mixed by titrating
approximately 100 times. The 30 ul mixture was placed under a clean cover slip situated
on top of a hemacytometer. The hemacytometer is used for cell counting which allows
an approximation of the number of cells present within the T75 flask to be calculated.
This was accomplished by counting the number of cells within the squares located in the
4 corners and the square located directly in the middle of the hemacytometer. The cells
located on the left and upper borders of each square designated for counting were
considered to be a part of that square and were also counted. If over 90% of the cells
were in contact with other cells, the sample would be re-done due to the calculations not
being a correct representation. The number of cells within each of the 5 squares were
added together then divided by 5, multiplied by 2, and then multiplied by 10^4. The final
number represented the number of cells per ml. These numbers were recorded and
used to observe the rates at which the cells were growing. The remaining selection
media within the 15 ml centrifuge tube was used for re-seeding the cells. 4.9 ml was
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placed into a new T75 flask and the remaining 4.9 ml was placed into another T75 flask,
both containing 8 ml of selection media.
To freeze the cells, the pellets for FAD and WT were re-dissolved in 1 ml of
freezing media. 10 ml of freezing media consisted of 1 ml of DMSO and 9 ml of FBS.
The contents were then transferred into cyro tubes and placed at -20 degrees Celsius for
approximately 1 hour. After, they were moved to -80 degrees Celsius to be stored
overnight. For long term storage the cyro tubes were placed in liquid nitrogen.
When the cells were received they were currently in their third passage;
therefore, the cells were observed, counted, frozen, and re-seeded, several more times
in order to acquire cells at passages 4, 5, 6, and 7. This process can be viewed by
looking at figure 2. Due to FAD cells growing at a faster rate then WT cells and them
becoming confluent at different times, the cells were sometimes split into 3 or 4 flasks,
allowing multiple vials of each passage for FAD and WT cells to be frozen and stored.
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Figure 2: Passage experiment flow chart. Explanation of which T75 flasks were frozen
and which ones were re-seeded in order to acquire cells at different passages.
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3. MTS Assay
Once cells were obtained from varying passages, the IC50 concentrations were
determined after the addition of OPP by carrying out the CellTiter 96 AQueous One
Solution Cell Proliferation Assay (Promega, Madison, WI). In order to prepare for this
assay, a vial of FAD and WT cells from each passage were thawed and placed in
separate T75 flasks containing 13 ml of media. They were allowed to grow until they
became 90% confluent within an incubator with the same specifications as stated earlier
in part 2. Each cell type, from each passage, was then counted using a hemacytometer
following the same guidelines discussed in section 2(b). Once the number of cells/ml
was determined, dilution factors were calculated in order to acquire approximately 5000
cells/100 ul. This was done in order to place roughly the same number of cells in each
well of the 96 well microtiter plate. Selection media was used to achieve these desired
dilutions. 100 ul of cells from each passage were then placed into all wells within the 96
well plates except for those located around the perimeter. A 96 well plate was used for
each type of cell and for each passage; therefore, there were plates for FAD cells in
passages 4, 5, 6 and 7, and for WT cells in passages 4, 5, 6, and 7.
The plates were placed into the incubator and left for approximately 24 hours to
allow the cells to attach. After the 24 hours, the media was removed from the wells using
a multi-channel pipette. 100 ul of fresh selection media was added to each well located
around the perimeter of the plate to be used as blanks and was also added to the first
and last columns of wells which contained cells in order to be used as controls. 100 ul of
differing OPP, from Malaysia, concentrations explained in figure 3 were added to
differing columns.
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Once the plates were incubated for 48 or 72 hours with varying OPP
concentrations, 10 ul of the CellTiter 96 Aqueous One Solution Reagent was added to
each well. It was also added to a few wells located around the perimeter of the plate in
order to acquire blanks. The plates were placed on a shaker approximately 30 seconds
and then incubated with the CellTiter 96 Aqueous One Solution Reagent for 3 hours. Each
plate was read at an absorbance of 490 nm using the Bio-Tek microplate reader (BioTek, Winooski, VT). Later, the MTS assay was completed using cells in passage 4 or
passage 7. This modification was made based on the results of the initial MTS assay
and was done in order to obtain more precise and accurate conclusions.
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Concentrations

OPP (ul)

Selection Media (ul)

Total Volume (ul)

100

10

990

1000

150

15

985

1000

200

20

980

1000

250

25

975

1000

300

30

970

1000

350

35

965

1000

400

40

960

1000

450

45

955

1000

Figure 3: Volumes of OPP and selection media used to obtain specific OPP
concentrations used for MTS assay.
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4. Statistical Analysis
Based on the data obtained from the Bio-Tek microplate reader, the three values
closest together were taken for each OPP concentration, control, and blank. These
values were then averaged and Microsoft Excel was used to calculate the standard
deviations. Data from different passages and OPP concentrations were compared using
the application of SPSS software. Values considered to be statistically significant had a
p value that was less then or equal to 0.5.
Specific Aim II (b): To investigate the effects of OPP on the protein expression of APP,
COX-2 and PARP, known biomarkers for AD and inflammation in FAD mutant and WT
cells.
1. Addition of OPP
In order to complete Western blot analysis, the cells had to be thawed from liquid
nitrogen and re-seeded. Despite the cells growing efficiently within the selection media
even at passage 7, it was determined that passage 4 of both FAD and WT cells would
be used. This decision was based on the results of the MTS assay and in order to be
certain the cells retained their AD characteristics. One cyro tube for each cell type, FAD
and WT, were thawed and seeded into 13 ml of selection media within T75 flasks. The
cells were incubated with the same specifications as stated earlier and left to grow until
they became 90% confluent. The cells were prepared by following the same procedures
for re-seeding stated in section 2 (a);however, instead of adding the dissolved pellet
back into a T75 flask,

five Petri dishes containing 10 ml of selection media each

received 200 ul of the cells. This was completed for passage 4 of FAD and WT cells for
a total of 10 Petri dishes. The Petri dishes were then rotated in order to evenly distribute
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the cells and then placed into the incubator overnight. After 24 hours, the plates were
viewed under the microscope to confirm attachment of the cells to the plate wall. If cells
were floating within the selection media they were considered to have lost their cDNA
construct; therefore, they needed to be re-seeded due to possible contamination.
After 24 hours, and the cells were confirmed to be attached to the Petri dishes,
the media was removed and 10 ml of the differing OPP concentrations were added to
different dishes. Based on the MTS assay results it was determined to use the OPP
concentrations of 150, 300, and 600 ul/ 10 ml. One Petri dish was used as a control and
10 ml of fresh selection media was added to it. The fifth Petri dish received an additional
OPP concentration of 600 ul/10 ml. This was done due to such a high concentration of
OPP possibly causing the cells growth to be so low that one plate would not produce
enough cells to carry out the experiment. The Petri dishes were then incubated for the
optimal time period of 72 hours.
2. Protein Extraction
Once the cells were incubated with the differing OPP concentrations, protein
extraction was completed. This experiment was conducted on ice in order to prevent
protein denaturation. The media was removed from each Petri dish and placed into
separate 15 ml centrifuge tubes. Each Petri dish was then scrapped with the addition of
1-3 ml of PBS and transferred into the corresponding 15 ml tube. The tubes were
centrifuged at 1,500 RPM for 3 minutes. The supernatant was removed and based on
the size of the pellet; the appropriate amount of lysis buffer (10X lysis buffer was diluted
to 1X) (Cell Signaling, Danvers, MA) containing protease inhibitor cocktail for
mammalian cells (Sigma Aldrich, Saint Louis, MO) was added. 200 ul of protease
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inhibitor was added to 1 ml of lysis buffer. Only 1 ml was mixed at a time due to the
protease inhibitor losing its properties after 30 minutes. Each of the 8 pellets was
dissolved into twice their volume of lysis buffer. Lastly, the contents were transferred into
1 ml centrifuge tubes and stored at -80 degrees Celsius overnight.
3. Protein Assay
After 24 hours, the protein samples were thawed and centrifuged. The cells were
spun at approximately 1,500 RPM while being maintained at -4 degrees Celsius. The
supernatant was then transferred into new 1 ml centrifuge tubes and the pellets were
discarded. The protein assay was carried out by using the Pierce BCA Protein Assay Kit
(Thermo Scientific, Logan, UT). By following the specifications made by this kit, the BSA
standards and the BCA working reagent were prepared. In a 96 well microtitier plate, 25
ul of each standard and each sample was added into 3 consecutive wells. The remaining
protein samples were placed back into -80 degrees Celsius until the Western blot
analysis could be completed. 200 ul of the BCA working reagent was then added into
each of the wells by using a multi-channel pipette. The plate was placed on a shaker for
approximately 30 seconds followed by 30 minutes of incubation at 37 degrees Celsius.
The plate was allowed to cool to room temperature and then read at an absorbance at
570 nm using a Bio-Tek microplate reader (Bio-Tek, Winooski, VT). If the absorbance of
the samples exceeded the maximum standard value, the samples were diluted. This was
carried out by adding 10 ul of each sample to 90 ul of deionized water before loading
them into the plate.
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4. Western Blot Analysis
Western blot analysis was carried out to see the effects OPP had on the protein
level of expression of COX-2 and PARP for FAD and WT cells. The first step completed
in order to carry out this experiment was to assemble the gel apparatus. The glass
plates were checked for leaks after being assembled and clamped. Once it was ensured
that there were no leaks, the separating and stacking gels were prepared.
The first gel prepared was a 20% polyacrylamide gel mix. The separating gel was
mixed and consisted of 5 ml of 30% acrylamide, 3.75 ml of 1.5 M Tris pH 8.8 (Bio-Rad,
Hercules, CA), 6.125 ml of deionized water, 75 ul of 20% sodium dodecyl sulfate (SDS),
150 ul of 10% ammonium sulfate, and 15 ul of tetramethylethylenediamine (TEMED)
(Acros Organics, Geel, Belgium). These solutions were mixed within a 15 ml centrifuge
tube and immediately added in between the 2 gel plates previously assembled. Using a
1 ml pipette the separating gel was added until it reached approximately 2.5 cm from the
top. If air bubbles were present within the gel, it was re-done. Deionized water was
added on top while the gel hardened. After approximately 20 minutes, the gel was
hardened and the water was removed by inverting the plate apparatus. To aid in the
removal of all the water, filter paper was carefully used to soak up any water that
remained.
After the separating gel was hardened, the stacking gel was prepared. For the
20% polyacrylamide gel, 2 ml of 30% acrylamide, 3.75 ml of 0.5 M Tris pH 6.8 (Bio-Rad,
Hercules, CA), 9.125 ml of deionized water, 75 ul of 20% SDS, 150 ul of 10%
ammonium persulfate, and 15 ul of TEMED were mixed via inverting the 15 ml centrifuge
tube. The stacking gel was added on top of the separating gel and a 10 well comb was
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placed into the gel. The comb remained in the gel until it completely hardened,
approximately 20 minutes.
While the gels were hardening, the supernatant of the protein samples acquired
earlier were prepared for loading. This was accomplished by first determining the protein
concentrations and the amount of volume needed for each sample. This was calculated
by using the data from the Pierce BCA Protein Assay Kit performed previously. The 3
values of protein concentrations provided by the Bio-Tek microplate reader in ug/ml were
averaged and then converted to ug/ul for each sample. The ug/ul value was divided into
40 producing the value for the amount of protein needed of that sample. Once the
calculations were computed, the samples were re-thawed by centrifuging them at -4
degrees Celsius at 2,000 RPM for approximately 1 minute. 5 ul of 6X loading buffer was
added to the appropriate amount of protein followed by the addition of enough 1X
loading buffer to bring the total volume of each sample up to 30 ul. These calculations
were preformed in order to have an equal volume of protein for each sample. Once the
protein samples were prepared, they had to be denatured. This was accomplished by
wrapping them with parafilm and placing them in boiling water for 5 minutes.
After the gel and protein samples were prepared, the samples were loaded into
the gel. The 10 well comb was removed and 30 ul of each sample was loaded into
separate wells. In order to be able to compare the samples to a standard, one well
received 30 ul of the Full Range Rainbow Marker (Fisher Scientific, Pittsburgh, PA) and
another well received 30 ul of the Magic Mark XP Western Standard (Invitrogen,
Carlsbad, CA). The gels were than ran at 50 mA in a Bio-Rad electrophoresis (Bio-Rad,
Hercules, CA) with 1X electrode tris-glycine-SDS (TGS) (Bio-Rad, Hercules, CA) running
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buffer. Once the bands passed through the stacking gel and entered the separating gel,
the voltage was reduced to 35 mA. When the samples reached the bottom of the gel the
machine was turned off.
After, the samples were run through the gel; it then had to be transferred onto a
nitrocellulose membrane (Whatman, Piscataway, NJ). The first step in this process was
to carefully remove the gels from the glass plates and remove the stacking portion. The
gel was then placed on an equally sized piece of the nitrocellulose membrane which was
placed on top of 3 equally sized pieces of filter paper. Once the gel was carefully placed
and all air bubbles were removed, 3 more pieces of filter paper were placed on top and
all components were placed on a Semi-Dry Transfer Blot Apparatus (AA Hoefer,
Holliston, MA). Transfer buffer was used to soak the membrane and filter papers and
was also added to the transfer apparatus. This buffer consisted of, 700 ml of deionized
water, 100 ml of TGS buffer (Bio-Rad, Hercules, CA) and 200 ml of methanol. The
transfer apparatus was ran for 90 minutes at a voltage of 80 mA.
After the gel was transferred to the membrane, it was incubated with the primary
antibody. First, the membrane was washed with 1X phosphate buffered saline (PBS) for
5 minutes. 10X PBS was prepared by dissolving 80 grams of sodium chloride (NaCl), 2
grams of potassium chloride (KCl), 14.4 grams of disodium hydrogen phosphate
(Na2HPO4), and 2.4 grams of potassium dihydrogen phosphate (KH2PO4) in 800 ml of
deionized water. The pH was adjusted to 7.4 by adding either HCl or NaOH and then
enough deionized water was added to bring the total volume to 1 liter. The 10X PBS was
then diluted to 1X PBS with the use of deionized water. Secondly, the membrane was
blocked with 25 ml of 5 grams of bovine serum albumin (BSA) (Sigma Aldrich, Saint
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Louis, MO) dissolved in 100 ml of 1X PBS (5% BSA) for 2 hours. Once it was blocked, it
was washed for 10 minutes with 1X PBS three times. The primary antibodies used were
COX-2 (Novus Biologicals, Littleton, CO), 22C11 Anti-Alzheimer Precursor Protein A4
(Millipore, Temecula, CA), beta tubulin (Novus Biologicals, Littleton, CO), PARP 46D11
(Cell Signaling, Danvers, MA) and beta-actin (Cell Signaling, Danvers, MA). Each
primary antibody was diluted to a 1 to 1000 ratio; therefore, 10 ul of the antibody was
added to 10 ml of 5% BSA. The membrane was placed into a plastic bag, the diluted
antibody was added, and all sides of the bag were sealed. The membrane was placed at
4 degrees Celsius on a shaker with high agitation overnight.
After the membrane was incubated with the primary antibody, it was then
incubated with the secondary antibody. This was accomplished by first washing the
membrane with PBS-Tween (PBS-T) (0.1% of tween added in 1 liter of 1X PBS) (Fisher
Scientific, Pittsburgh, PA) 3 times with each wash lasting for 10 minutes. It was then
incubated with the secondary antibody for 2 hours. Depending on the primary antibody
used, either the goat anti-rabbit HRP conjugate (Bio-Rad, Hercules, CA) or the antimouse monoclonal antibody (Cell Signaling, Danvers, MA) was used. The goat antirabbit antibody was used for the primary antibodies, beta-actin, COX-2, PARP and beta
tubulin, while the anti-mouse antibody was used for 22C11. These antibodies required
different dilutions, however, it was discovered that they both worked the best with a
1:4000 dilution. This meant that 6.25 ul of the secondary antibody was added to 25 ml of
5% BSA. After the 2 hour incubation period, the membrane was washed with PBS-T four
times, each one lasting for 5 minutes. Once the washes were completed, the membrane
was read using the Bio-Rad ChemiDoc XRS molecular imager (Bio-Rad, Hercules, CA).
The membrane was sprayed evenly 2 to 3 times with a Calbiochem RapidStep ECL
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reagent (Biocompare Billercia, MA). After spraying, the Bio-Rad molecular imager was
used to calculate the band densities for COX-2, APP, PARP, beta tubulin, and betaactin. Using beta-tubulin or beta-actin primary antibodies, the results for COX-2, APP,
and PARP were normalized against it.
Due to a membrane only being able to be incubated with one primary antibody at
a time, the membrane had to be stripped in order to achieve results for an additional
biomarker. This was accomplished by stripping the membrane with 10 ml of Restore
Western Blot Stripping Buffer (Thermo Scientific, Logan, UT) and placing it on high
agitation for 10 minutes. The membrane was then washed with 1X PBS for 5 minutes
followed by repeating the procedures for blocking with 5% BSA, primary incubation, and
secondary incubation. Once the band densities for the desired biomarkers were obtained
by using Quantity One software along with the Bio-Rad Molecular imager, calculations
were made and imported into Microsoft Excel.
Specific Aim III: To investigate the effect of OPP on the mRNA expression of COX-2
and amyloid precursor protein (APP) in FAD mutant and WT cells using real time RTPCR.
1. Preparation of Cells
The cells were prepared for real-time PCR by following the same guidelines
discussed in specific aim II, step 1. Cells for FAD and WT that were maintained in liquid
nitrogen at passage 4 were incubated in Petri dishes with OPP concentrations of 150,
300, and 600 ul/10 ml.
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2. RNA Extraction
RNA extractions were completed for all samples using a miRNeasy Mini Kit and
QIAzol Lysis reagent (QIAGEN Inc., Valencia, CA). All steps were carried out while on
ice in order to try and prevent RNA denaturation. The cells were collected from the Petri
dishes by following the procedures discussed in specific aim II, step 2, but stopping
before lysis was added. Once the pellets were formed, they were loosened by flicking
the tubes. 700 ul of QIAzol Lysis reagent was then added. Each tube was vortexed for 1
minute or until cells were homogenized completely and placed at room temperature for 5
minutes. 140 ul of chloroform was added to each tube and mixed thoroughly by shaking
vigorously. The samples were then left to stand at room temperature for 2 to 3 minutes.
With the centrifuge being maintained at -4 degrees Celsius the tubes were spun at
12,000 x g for 15 minutes. This caused the samples to separate in 3 different phases.
The phase containing the RNA was the upper, colorless, aqueous phase; therefore, this
phase was removed and placed into a new collection tube provided by the miRNeasy
mini kit.
After acquiring the RNA phase, 525 ul of 100% ethanol was added to the
collection tubes and mixed thoroughly via titration. An Rneasy mini column was placed
into a 2 ml collection tube and 700 ul of each sample was added. The samples were
subsequently centrifuged at 10,000 RPM for 15 seconds while at room temperature. The
content collected within the 2 ml collection tubes was discarded. The remainder of the
sample was added in 700 ul increments until the entire sample was spun through the
Rneasy column. After each spin, the content in the collection tube was discarded. 700 ul
of Buffer RWT was added into the Rneasy column and then centrifuged at 10,000 RPM
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for 15 seconds. The flow through was discarded. 500 ul of Buffer RPE was then added
into the Rneasy column and also centrifuged at 10,000 RPM for 2 minutes. The addition
of Buffer RPE and centrifugation was repeated in order to dry the Rneasy column
membrane. The Rneasy columns were placed into new 2 ml collection tubes and
centrifuged at full speed for 1 minute. To collect the RNA, the Rneasy columns were
then transferred into 1.5 ml collection tubes and 50 ul of Rnase-free water was added
onto the column. The tubes were centrifuged for 1 minute at 10,000 RPM. The contents
in the 1.5 ml collection tubes were placed back through the Rneasy column and recentrifuged. This step was completed in order to increase the yield of RNA collected.
The contents within the 1.5 ml collection tubes contained the desired RNA.
It should be noted that these steps were completed on ice unless otherwise
stated by the miRNeasy mini kit and all materials used were Rnase free. Most tubes
were provided by the kit; however, for any additional steps completed such as ensuring
the Rneasy column was dry, the tubes were only used if they were new and Rnase free.
This was done to prevent denaturation and to ensure the collection of purified RNA. A
nanodrop spectrophotometer machine (Thermo Scientific, Logan, UT) was used to
quantify the RNA.
3. Complementary DNA (cDNA)
Once the RNA was extracted and purified, it was immediately converted to
cDNA. This was carried out by using a high capacity RNA-to-cDNA master mix (Applied
Biosystems, Carlsbad, CA). Calculations were completed to determine the amount of
each sample needed in order to achieve approximately 1ug/ul in a 20 ul volume. Once
the samples were diluted to the same concentrations using Rnase free water, 12 ul of
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the diluted RNA sample was mixed with 12 ul of Rnase free water, and 6 ul of Complete
Master Mix. Each sample was titrated and then placed in an Eppendorf Realplex
thermocycler (Eppendorf, Hauppauge, NY). The parameters used to produce the cDNA
were as follows; 5 minutes at 25 degrees Celsius, 30 minutes at 42 degrees Celsius, 5
minutes at 85 degrees Celsius, and held at 4 degrees Celsius. The samples were then
stored at -80 degrees Celsius until amplification of specific genes could be carried out.
4. Real-Time Polymerase Chain Reaction (PCR)
Once cDNA was made from RNA, the genes of interest were amplified. The first
step in this process was preparing the forward and reverse primers. The control gene,
GAPDH (glyceraldehyde 3-phosphate dehydrogenase), (Invitrogen, Carlsbad, CA) was
used to normalize genes expressing COX-2 and APP. The forward primer for APP was
5’-GATGTCTTGGCCAA

CATGAT-3’

and

the

reverse

primer

was

5’-

CATCTGCTCAAAGAACTTGTA-3’ (Invitrogen, Carlsbad, CA). The forward primer used
for COX-2 was 5’-GACAGCAGCC CTCTCATTTC-3’ and the reverse primer was 5’CTGCTCCAAGACTGGCTCTC-3’ (Invitrogen, Carlsbad,

CA).

Each primer

was

reconstituted and then diluted to 20% using nuclease water. For each gene, GAPDH,
COX-2, and APP, 12.5 ul of SYBR green (Applied Biosystems, Carlsbad, CA), 2 ul of the
reverse primer, 2 ul of the forward primer, and 6.5 ul of nuclease free water were
combined together. For a total of 8 samples, triplicates for each sample, and with a
control, a total of 25 reactions were needed for each gene. Once the genes were
prepared, 23 ul of each one was placed into 25 wells of a 96 well plate. This was
completed for GAPDH, COX-2 and APP. The cDNA samples were removed from -80
degrees Celsius and centrifuged. 2 ul of each sample was added and titrated into 3 wells
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for each gene. After all 8 samples were added, 2 ul of nuclease free water was added to
one well for each gene in order to be used as a negative control. The plate was capped,
spun down at -4 degrees Celsius, and amplified using an Eppendorf Realplex
thermocycler. The samples were amplified with the parameters set at 95 degrees
Celsius for 10 minutes, 40 cycles of 95 degrees Celsius for 15 seconds followed by 60
degrees Celsius for 1 minute, 95 degrees Celsius for 1 minute, 60 degrees Celsius for
30 seconds, temperature increase to 95 degrees Celsius over a 20 minute time period
and the final step of 95 degrees Celsius for 30 seconds. Once the amplification process
was completed, calculations were done to determine the fold increase with GAPDH
being used to normalize the samples. A change less then a two fold difference was
considered to be insignificant.
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CHAPTER 3
RESULTS
Specific Aim I: To determine the anti-amyloidogenic activities of OPP, if any, by
measuring the inhibition of formation and destabilization of amyloid beta proteins using a
thioflavin T (ThT) binding assay.
This experiment was conducted to determine if OPP has any anti-amyloidogenic
activities. This was accomplished by carrying out a ThT binding assay to see if OPP can
prevent the formation of and/or aid in the destabilization of Aβ1-42 proteins. Although for
both assays the data was collected every 30 minutes over a 24 hour period, the number
of data points plotted was reduced in order to better show the trend.
Figure 4 shows the data obtained from the destabilization assay. The ThT
fluorescence is relative to the amount of Aβ plaques formed. The fluorescence for the
sample control, no OPP, remained low and nearly constant, ±0.2 units. Thus, this
represents no effect on Aβ plaque destabilization. The sample with an OPP
concentration of 300 ul/10 ml, displayed a decrease in fluorescence, indicating a
decrease in the number of Aβ plaques. This is evident when looking at the starting value
which was calculated to be approximately 1 while the end value was 0.4. Figure 4 shows
the decrease in fluorescence during a 12 hour period for both the OPP control sample
and the OPP 300 ul/10 ml sample. It illustrates that the OPP 300 ul/10 ml sample had a
greater decrease in the number of Aβ plaques then the OPP control sample. Although
the values are relative to 1, the data shows that OPP is indeed aiding in the
destabilization of Aβ plaques in comparison to the sample control.
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While the destabilization assay showed the effect OPP had on Aβ plaques;
unfortunately, the inhibition for formation assay did not. The effect of OPP on Aβ
formation needs to be investigated further. Experimental error may have played a part in
this assay; therefore, this information cannot be reported without confirmation.
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Figure 4: Destabilization ThT binding assay. The destabilization of Aβ 1-42 proteins with
the addition of an OPP concentration of 300 ul/10 ml in comparison to Aβ 1-42 proteins
without OPP. Differences in values shown between the first 12 hours. ThT fluorescence
values were determined by averaging three values and subtracting appropriate controls.
Values are relative to 1.
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Specific Aim II (a): To determine the effect of OPP on cell growth and viability of the
FAD-mutant cell constructs with increase in passage using MTS assay.
This assay was conducted in order to determine the number of passages the
cells could go through without losing their cDNA construct. This was accomplished by
counting the number of cells in each flask as well as growing them in a selection media.
If either the FAD or WT cells lost their cDNA construct, they would not be able to grow in
the flask. When completing the passage assay, the cells continued to grow in the
selection media up to and through passage 7. The numbers of cells were also counted
each time they were removed to be re-seeded and frozen. With the cells still viable to
grow in the selection media, the number of cells increased with each passage. This
assay showed that the B103 rat neuroblastoma cells would maintain their cDNA
construct through passage 4, 5, 6, and 7, meaning that the FAD mutant cells would
maintain their AD-like characteristics.
The MTS assay was conducted in order to determine the IC50 concentrations of
the FAD and WT cells in passage 4 and 7 when incubated for 48 or 72 hours with
varying OPP concentrations. The purpose of this experiment was to find the optimal
incubation period, cell passage, and OPP concentration. These parameters were vital to
find at the beginning in order to use them throughout the rest of the experiments and
maintain consistency. Since the cell lines used were rat neuroblastoma cells, the optimal
concentration of OPP needed to show a significant effect on the cells without causing
excessive cell death.
The first MTS assay completed tested the effects of OPP concentrations
between 100 and 450 ul/ 10 ml on cells in passage 4 for a 48 hour incubation period.
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Figure 5 shows the effects these parameters had on FAD cells. Using SPSS software, it
was calculated that all OPP concentrations were statistically significant from the control
(no OPP). The procedures for these calculations was described in the materials and
methods section 2 (4). The IC50 concentration was calculated to be approximately 250
ul/10 ml. Figure 6 shows FAD cells in the same passage with identical OPP
concentrations; however, the incubation period was extended from 48 hours to 72 hours.
This was completed to compare varying time periods of incubation and determine the
optimal period to be used for following experiments. When the FAD cells were incubated
for 72 hours, data analysis determined that all OPP concentrations were statistically
significant when compared to the control. There was a difference in the IC50
concentration when comparing 48 hours vs. 72 hours; the IC50 concentration at 72 hours
was approximately 225 ul/10 ml.
Once the incubation time periods were compared for FAD cells, the passage at
which they were frozen and then used was tested. Using B103 rat neuroblastoma cells
transfected with a cDNA mutation means the more passages you carry out with them,
the higher the possibility that they will begin to lose their mutation characteristics.
Passage 4 was the state at which the cells were received and then allowed to grow;
therefore, that passage was compared to passage 7 to see if there were any variances
in the data. Figure 7 shows the effects of varying OPP concentrations on FAD cells in
passage 7 after 48 hours of incubation. All OPP concentrations were found to be
statistically significant from the control and the IC50 concentration was determined to be
approximately 300 ul/10 ml. FAD cells in passage 7 were also incubated for 72 hours
and can be seen in figure 8. Unlike the previous data, all varying OPP concentrations
except for 100 ul/10 ml were determined to be statistically significant from the control.
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The calculated IC50 concentration was approximately 325 ul/10 ml. After the effects of
differing parameters on FAD cells were established, WT IC50 concentrations were
determined for passages 4 and 7 during incubation time periods of 48 and 72 hours with
varying OPP concentrations.
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Figure 5: MTS assay results for FAD cells in passage 4 and with a 48 hour incubation
period with various OPP concentrations. *P < 0.05 when compared to the untreated
control.

Figure 6: MTS assay results for FAD cells in passage 4 and with a 72 hour incubation
period with various OPP concentrations. *P < 0.05 when compared to the untreated
control.
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Figure 7: MTS assay results for FAD cells in passage 7 and with a 48 hour incubation
period with various OPP concentrations. *P < 0.05 when compared to the untreated
control.

Figure 8: MTS assay results for FAD cells in passage 7 and with a 72 hour incubation
period with various OPP concentrations. *P < 0.05 when compared to the untreated
control.
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Once the effects of varying parameters on FAD cells were determined, WT cells
were then tested. As with the FAD cells, WT cells in passage 4 were first incubated for
48 hours with OPP concentrations varying between 100 and 450 ul/10 ml. As shown in
figure 9, all OPP concentrations were found to be statistically significant from the control.
The IC50 concentration was calculated to be apprioxmately 275 ul/10 ml. Increasing the
incubation time period to 72 hours was then completed and that data is shown in figure
10. Again, it was found that all of the OPP concentrations were stastistically significant
when compared to the control. The IC50 concentration was calculated to be
approximately 250 ul/10 ml.
After the incubation time periods were compared while the WT cells were in
passage 4, they were then tested in passage 7. Figure 11 shows the effects of varying
OPP concentrations on WT cells incubated for 48 hours while in passage 7. The data
shows that all OPP concentrations except for 100 ul/ 10 ml were statistically significant
from the control. The IC50 concentration was also calculated and determined to be
approximately 250 ul/10 ml. WT cells in passage 7 were then incubated for 72 hours.
This data can be seen in figure 12. Unlike the other data, this graph shows a greater
variation between the differing OPP concentrations. The only OPP concentrations shown
to be statistically significant when compared to the control were between 250 ul/10 ml
and 450 ul/10 ml. Despite the larger variations, the IC50 concentration was calulcated to
be the same as the 48 hour incubation period with passage 7; an OPP concentration of
250 ul/10 ml.
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Figure 9: MTS assay results for WT cells in passage 4 and with a 48 hour incubation
period with various OPP concentrations. *P < 0.05 when compared to the untreated
control.

Figure 10: MTS assay results for WT cells in passage 4 and with a 72 hour incubation
period with various OPP concentrations. *P < 0.05 when compared to the untreated
control.
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Figure 11: MTS assay results for WT cells in passage 7 and with a 48 hour incubation
period with various OPP concentrations. *P < 0.05 when compared to the untreated
control.

Figure 12: MTS assay results for WT cells in passage 7 and with a 72 hour incubation
period with various OPP concentrations. *P < 0.05 when compared to the untreated
control.
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The optimal parameters were detemined after all the data was collected and
calculated. This assay was completed three different times all producing similar results.
When the data between the cells in passage 4 and passage 7 are compared, it is
evident that the passages are behaving differently. The cells in passage 4 illustrated a
more uniform graph showing a slow, clean, dose dependent curve at both time points.
This is evident when comparing figure 6 showing FAD cells in passage 4 for a 72 hour
incubation period to figure 8 showing FAD cells in passage 7 for a 72 hour incubation
period. Using the same data from figures 6 and 8, figure 13 further illustrates this point.
The abosorbanices for both passage 4 and passage 7 were graphed on a scatter plot
and a trendline with an order of 4 was added. Based on these results, it is logical to
select passage 4 for the following experiments.
The other important parameter determined with the MTS assay was the optimal
incubation time period. When comparing 48 hours vs. 72 hours, it was decided that for
the remaining experiments the cells would be incubated with the OPP concentrations for
72 hours. This decision was based upon the data showing greater variances in the
absorbances of samples after 72 hours of incubation. The data for 48 hours showed a
steady decrease in the samples absorbances as the OPP concentations increased;
however, the larger variances in the sample aborbances after 72 hours illustrated that
the OPP had a greater effect on the cells. This can be confirmed by comparing the
results of the first assay, which can be seen by looking at figure 5 and figure 6. For FAD
cells in passage 4 with a 48 hour incubation period, the control sample absorbance was
calculated to be 1.202 and the OPP 450 ul/10 ml sample absorbance was determined to
be 0.295. For FAD cells incubated for 72 hours, the control sample absorbance was
1.424 while the OPP 450 ul/10 ml sample absorbance was calculated to be 0.187. The
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greater decrease in samples absorbance when compared to the controls was evident
during the 72 hour incubation period. This variance also occurred for WT cells in
passage 4. For this reason, both the FAD and WT cells would be incubated with the
OPP for a total of 72 hours for the remaining experiments.
Lastly, the optimal OPP concentration was determined to be 300 ul/10 ml. This
conclusion was based on the calculated IC50 concentrations. The IC50 concentrations
ranged between 225 and 325 ul/10 ml for FAD cells and between 250 and 275 ul/10 ml
for WT cells. Due to these calculations, it was decided that the optimal OPP
concentration to be used for the remaining experiments would be 300 ul/10 ml.
Although comparing the incubation time periods, OPP concentrations, and
passages were important in order to find the optimal parameters to be used in following
experiments, comparing the WT to FAD cells also provided essential information. To
compare FAD vs. WT cells the absorbance of the controls were compared against the
values of the absorbance for the samples containing an OPP concentration of 450 ul/10
ml. This was done in order to see if OPP had a greater effect on the FAD cells when
compared to the WT cells. Since the optimal parameters were determined to be cells in
passage 4 with a 72 hour incubation period, figure 6 and figure 10 were compared. The
FAD control absorbance was calculated to be 1.424 while the OPP 450 ul/10 ml sample
absorbance was 0.187 . This made the difference between the control and OPP sample
to be 1.237. The WT control absorbance was determined to be 0.671 while the OPP 450
ul/10 ml sample absorbance was 0.154. The difference calculated between these two
values was 0.517. These calculations show that the addition of OPP had a greater effect
on FAD cells when compared to WT cells, do to the larger decrease in absorbance
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between the control and the sample containing an OPP concentration of 450 ul/10 ml.
This comparision is further illustrated in figure 14. It should also be noted that the OPP
450 ul/10 ml samples for both the FAD and WT cells had an absorbance of
approximately 0.19.
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Figure 13: Graph showing the absorbance for FAD cells incubated for 72 hours in
passage 4 vs. FAD cells incubated for 72 hours in passage 7. A trendline with an order 4
was added in order to illustrate that the cells in passage 4 produced a more uniform,
clean, dose dependent curve when compared to the cells in passage 7.
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Figure 14: Graph showing the absorbance for FAD cells incubated for 72 hours in
passage 4 vs. FAD cells incubated for 72 hours in passage 7. A trendline with an order 4
was added in order to illustrate that the cells in passage 4 produced a more uniform,
clean, dose dependent curve when compared to the cells in passage 7.
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Figure 15: The change in absorbance between the sample control and OPP 450 ul/10
ml sample for FAD and WT cells. Shows a greater effect of OPP on FAD cells then when
compared to WT cells.
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Specific Aim II (b): To investigate the effects of OPP on the protein expression of APP,
COX-2 and PARP, known biomarkers for AD and inflammation in FAD mutant and WT
cells.
The protein expression levels of APP, COX-2 and PARP were measured using
western blot analysis. The optimal OPP concentration was determined to be
approximately 300 ul/10 ml; therefore, the cells were incubated with OPP concentrations
of 150, 300, and 500 ul/10 ml. APP was tested in order to determine if OPP could
directly affect the amount of APP produced at the protein level within the cells. The
picture of the membrane incubated with the antibody 22C11 (Millipore, Temecula, CA)
was taken using the BioRad molecular imager and is shown in figure 15a. The 22C11
antibody recognizes three specific isoforms of APP. Using the molecular weight marker it
was determined that the bands measured were at the molecular weights specified by the
22C11 antibody; ~110 kda, ~120 kda, and ~130 kda. The isoform at ~110 kda
represents immature APP, while the isoform at ~120 kda corresponds to sAPP and ~130
kda signifies the mature APP isoform.
With the bands from the membrane confirmed to be the isoforms of APP, they
were then measured as a whole and normalized against the band densities of beta actin
obtained on the same membrane. This data is represented in figure 15b. These results
show that the highest amounts of total APP expressed were found in the FAD control
sample. This result was expected due to the FAD cells having a mutation to produce
excess amounts of APP such as in the brain of an individual with AD. Additionally, as the
concentration of OPP increased, the amount of total APP expressed in the FAD cells
decreased. Not only did the OPP decrease the total amount of APP expressed, but it
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was shown to lower it to a level expressed in the WT control sample. Further, OPP
shows a slight reduction in APP levels even in the WT cells. These results show that an
OPP concentration of 300 ul/10 ml may reduce the amount of APP expressed at the
protein level to that of cells without the AD mutation. When extrapolated to humans, it
reflects reduction of APP levels to those of an individual without AD.
The protein level of expression of COX-2 was also measured using the western
blot analysis method. The same OPP concentrations of 150, 300, and 500 ul/10 ml were
used. The membrane was incubated with the primary antibody COX-2 which produced
the raw data that can be seen in figure 16a. The molecular weight marker was compared
to the bands produced on the membrane to confirm that they represented COX-2. Once
confirmed, the band densities were measured and then normalized against the
measured band densities for beta actin. The band densities were graphed and can be
viewed by looking at figure 16b.
The normalized data shows that the FAD control expressed the highest amount
of COX-2. Once OPP was added, the amount of COX-2 expressed decreased
significantly. Again, it should be noted that the addition of OPP decreased the levels of
COX-2 to approximately the same level as the WT control.
Lastly, the PARP protein expression levels were measured. A membrane
containing samples with OPP concentrations of 150, 300 and 500 ul/10 ml was
incubated with the PARP 46D11 primary antibody. The membrane was viewed using the
BioRad molecular imager and the bands were confirmed to represent PARP. The raw
membrane can be seen in figure 17a. The bands for PARP were then measured and
normalized against the band densities for beta actin. The normalized data can be viewed
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by looking at figure 17b. As with COX-2 and APP, the highest levels of PARP protein
expression was observed in the FAD control. A dose dependent decrease in PARP
expression is seen upon addition of OPP. It should be noted that due to a small sample
of cells, the membranes were stripped in order to measure more then one antibody per
assay. The band densities were measured immediately following the western blot;
however, the pictures were taken at a different time. Due to these procedures, the
pictures of the membranes may seem to differ from the data obtained and then plotted.
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Figure 16a: The membrane from western blot analysis incubated with the 22C11
antibody. This was used in order to recognize the protein levels of expression of the
three isoforms of APP (immature at ~110 kda, sAPP at ~120kda, and mature at
~130kda) for both the controls and varying OPP concentrations for FAD and WT B103
cells.

Figure 16b: The band densities (INT/mm2) for total amyloid precursor protein
normalized against the band densities for beta actin (INT/mm2) for both FAD and WT
B103 cells for controls and each varying OPP concentrations (ul/10 ml).
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Figure 17a: The membrane from western blot analysis incubated with COX-2 antibody.
It was used in order to recognize the protein expression levels of cyclooxygenase-2 for
both the controls and varying OPP concentrations for FAD and WT B103 cells.

Figure 17b: The band densities for cyclooxygenase-2 (INTmm2) normalized against the
band densities for beta actin (INT/mm2) for both FAD and WT B103 cells including
controls and each varying OPP concentrations (ul/10 ml).
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Figure 18a: The membrane from western blot analysis incubated with the cleavedPARP antibody. It was used in order to recognize the protein expression levels of poly(ADP-ribose) polymerase for both the controls and varying OPP concentration
incubations for FAD and WT B103 cells.

Figure 18b: The band densities for poly-(ADP-ribose) polymerase (INT/mm2)
normalized against the band densities for beta actin (INT/mm2) for both FAD and WT
B103 cells for controls and each varying OPP concentrations (ul/10 ml).
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Specific Aim III: To investigate the effect of OPP on the mRNA expression of COX-2
and amyloid precursor protein (APP) in FAD mutant and WT cells using real time RTPCR.
Once the protein expression levels were calculated and obtained, the
experimentation was taken one step further. This specific aim was conducted in order to
see if OPP could effect the expression of COX-2 and APP at the mRNA level. This was
accomplished by using real time PCR. The OPP concentrations used for these
experiments were 150, 300 and 600 ul/10 ml. After the data was collected it was
normalized against GAPDH. Analysis was then done to convert the data into a fold
difference. Any fold change greater then 2 times is considered to be significant.
The first real time PCR completed tested the mRNA expression levels of APP for
FAD cells. The fold change can be seen by looking at figure 18. Although slight
increases upon the addition of OPP are seen, this is not statistically significant. This is
due to there being less then a two fold difference between the values. The mRNA
expression levels were then tested for WT cells. This data can be seen in figure 19. For
this assay, the control sample and OPP 150 ul/10 ml sample were considered to be
statistically insignificant. This was found to be the same for the OPP 300 ul/10 ml and
OPP 500 ul/10 ml samples as well. However, when comparing the OPP control and OPP
150 ul/10 ml sample to the OPP 300 ul/10 ml and OPP 500 ul/10 ml samples, they were
found to be statistically significant from one another. This shows that in WT cells, an
OPP concentration of 300 or 500 ul/10 ml will significantly decrease the levels of APP
expression.
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Figure 19: The fold change of the mRNA expression of amyloid precursor protein
normalized with GAPDH for FAD control and samples with the OPP concentrations of
150, 300, and 600 (ul/10ml). * = statistically significant due to a two fold difference or
greater.
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Figure 20: The fold change of the mRNA expression of amyloid precursor protein
normalized with GAPDH for WT control and samples with the OPP concentrations of
150, 300, and 600 (ul/10ml). * = statistically significant due to a two fold difference or
greater.
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Lastly, the mRNA expression levels of COX-2 were measured in FAD and WT
cells. Figure 20 shows the fold differences for FAD cells. The OPP 150 ul/10 ml sample
was calculated to be statistically significant from the FAD control as well as the OPP 300
and OPP 600 ul/10 ml samples. The OPP 150 ul/10 ml sample was shown to have the
highest level of COX-2 mRNA expression. COX-2 was then tested in WT cells. This data
is shown in figure 21. For WT cells it was calculated that the OPP 300 ul/10 ml sample
was statistically significant from the WT control and OPP 150 ul/10 ml sample. Also, the
OPP 600 ul/10 ml was determined to be statistically significant from all other samples;
WT control, OPP 150 and OPP 300 ul/10 ml.
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*

Figure 21: The fold change of the mRNA expression of cyclooxygenase-2 normalized
with GAPDH for FAD control and samples with the OPP concentrations of 150, 300, and
600 (ul/10ml). * = statistically significant due to a two fold difference or greater.
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Figure 22: The fold change of the mRNA expression of cyclooxygenase-2 normalized
with GAPDH for WT control and samples with the OPP concentrations of 150, 300, and
600 (ul/10ml). * = statistically significant due to a two fold difference or greater.
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DISCUSSSION
Alzheimer’s disease (AD) is a very debilitating type of dementia that is affecting
approximately 35.6 million people in the world today (33). Of that population, 5.4 million
reside in the United States. AD is a progressive disease and has been determined to be
the 6th leading cause of death within the United States. Currently, an individual develops
AD every 69 seconds (29). Due to the baby boomer population vastly approaching the at
risk age of 65 years old, the importance for finding a treatment is becoming more crucial.
By the year 2050, the prevalence of AD is expected to rise to the point at which an
individual develops it every 33 seconds. With a 66% increase in AD associated deaths
between the years 2000 and 2008 and with an increasing at risk population; a treatment
discovery is vital (29).
The first sign of AD occurs when an individual is unable to retain new
information. This is due to neuronal cell death occurring in the region of the brain
responsible for forming new memories. Damage from neuronal cell death begins to
spread to other regions of the brain causing the individuals symptoms to worsen.
Besides certain recognizable symptoms such as confusion with orientation of time and
place, the diagnosis of AD is difficult. Often times the individual attributes their loss of
memory to the normal ageing process causing the diagnosis to go undetected (29).
However, even when the symptoms are recognized as AD, a diagnosis can only be
confirmed once the individual has passed away and an autopsy of the brain can be
completed (37). Without having accurate assessment tests, physicians often rely on the
patients’ history and an MRI of the brains physical appearance. Due to the difficulty of
diagnosing AD, some studies suggest approximately 80% of the AD cases have gone
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unnoticed (29). Without the etiology of AD being well known, it is difficult to diagnose
and/or treat (24).
AD can be further defined by either non-familial AD or familial AD (FAD). Nonfamilial AD can be classified as early-onset, under the age of 65, or late-onset, over the
age of 65. Non-familial AD is the most prevalent form while approximately only one
percent of the population is diagnosed with FAD. The etiology of FAD and non-familial
AD is not well known; however, there have been rare genetic mutations discovered to
cause FAD (24, 29). These mutations affect the chromosomes responsible for the
production of the amyloid precursor protein, presenilin 1 proteins, and for the presenilin 2
proteins (29). These proteins contribute to the development and progression of certain
AD characteristics.
One of the most prevalent and well known hallmarks of AD is the production and
formation of amyloid beta (Aβ) plaques. The amyloid precursor protein (APP) is a vital
protein that mediates neurite outgrowth and produces chemicals that are important for
the maintenance and formation of neuronal synapses (37). The problem for AD
individuals occurs when γ-secretase yields the Aβ1-42 fragment at a higher rate then in
non-AD individuals. Due to established genetic mutations for FAD, it is known that the
presenilin 1 and presenilin 2 proteins play a role in this rate of production (4). In non-AD
individuals, their body is able to clear out most of the Aβ1-42 fragments produced;
however, AD individuals produce an excessive amount ultimately creating a buildup of
the fragments (7). Once the Aβ1-42 fragments accumulate and create a plaque,
additional pathways are triggered causing microglial activation, ROS formation, oxidative
stress and an increase in inflammation (4).
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With Aβ plaques somewhat understood, certain biomarkers have been
established to look at the progression and/or development of AD. This study focused
primarily on two biomarkers; cyclooxygenase-2 (COX-2) and poly-(ADP-ribose)
polymerase (PARP). COX-2 plays a vital role in the inflammatory pathway. Looking at
figure 22 it can be seen that COX-2 is a rate limiting enzyme that regulates the
production of prostaglandins and cytokines (37). This is important due to prostaglandins
influencing the onset, magnitude, duration, and course of the inflammatory process (16).
As shown in figure 23, inflammation in AD individuals creates a continuous cycle of cell
apoptosis. ROS formation causes an increase in pro-inflammatory agents which then
leads to cell apoptosis, microglial activation, and additional pro-inflammatory agents
(28). Due to inflammation playing such an important role in the progression of AD, COX2 was examined in this study.
The other inflammatory biomarker looked at during this study was PARP. This
biomarker is known to regulate the release of pro-inflammatory agents by binding to and
altering the nuclear factor-kappa β (NF-kβ) transcription factor located on the DNA (36,
15). The NF-kβ is responsible for the regulation of macrophage and microglial activation
(11). As shown in figure 23, single strand DNA breaks, as a result from an increase in
oxidative stress, causes PARP to bind to the DNA and alter the NF-kβ transcription
factor (36). This then depletes cells energy pools leading to additional cell death. In
addition, this leads to an over production of microglial activation, which in turn increases
pro-inflammatory agents (15, 36).
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Figure 23: Flow chart showing the production and use of cyclooxygenase in the
inflammatory process.
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Figure 24: Flow chart showing the link between amyloid beta plaques, poly-(ADPribose) polymerase, call apoptosis, and the inflammatory process.
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The inflammatory biomarkers, PARP and COX-2, were used in this study
because of the strong link between inflammation and AD; however, they were also
chosen due to oil palm phenolics having high antioxidant capabilities. Oil palm phenolics
(OPP) are the water-soluble portions of the palm fruit. Currently, the fat-soluble portion is
being used as palm oil due to its rare fatty acid composition (27). While the fat soluble
portion is being used readily, the water-soluble portion is still being researched. It was
discovered that within the water-soluble portion, three major phenolics are present. Due
to the aromatic ring structure of phenolics, they have a high reduction-oxidation
potential, meaning they act as antioxidants (23). For this reason, this study examined the
effects OPP may have on the inflammatory biomarkers, PARP and COX-2, and its
association with AD.
First, OPP was examined to determine if it possesses any anti-amyloidogenic
capabilities. The ThT binding assay was conducted to test the effects of OPP on the
destabilization and also the inhibition of formation of Aβ1-42 plaques. The inhibition of
formation assay was inconclusive. Possibly due to experimental error, the effect OPP
has on the formation of Aβ plaques needs to be investigated further before a report can
be made. Unlike the inhibition of formation assay, the destabilization assay illustrated
that OPP did in fact aid in the destabilization of Aβ plaques. This is evident when looking
at the decrease in the ThT fluorescence over a 12 hour period for the sample containing
an OPP concentration of 300 ul/10 ml when compared to the sample control. The
decrease in the OPP 300 ul/10 ml sample fluorescence was approximately 0.6 while the
sample control fluorescence only decreased by approximately 0.06. Based on these
results it can be concluded that OPP may aid in the destabilization of Aβ plaques.
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After the ThT binding assay, a rat neuroblastoma B103 cell line, transfected with
a mutated cDNA construct to over express APP levels, were used. The first two assays
were conducted to determine if the cells maintained their AD characteristics throughout
different passages and also to discover the optimal parameters that would be used in the
following experiments. The passage experiment concluded that the cells maintained
their AD characteristics up to and through passage 7. The MTS assay determined that
the optimal OPP concentration was approximately 300 ul/10 ml of media, the optimal
incubation time period was 72 hours, and that using cells in passage 4 was ideal. Along
with these findings, the MTS assay also showed that OPP had a greater impact on FAD
cells then it did on WT cells. This could possibly show that due to FAD cells having an
increase in inflammatory agents, the OPP was able to use its antioxidant capabilities
more so then it could on the WT cells.
Western blot analysis was also completed. This experiment provided the band
densities for FAD and WT cells after being incubated with varying OPP concentrations.
The first biomarker looked at was complete APP. Looking at this data, it can be
concluded that OPP does in fact decrease the expression of APP at the protein level. By
comparing the band density of the FAD control to the FAD 300 ul/10 ml and FAD 500
ul/10 ml band densities, it shows a dramatic decrease in APP levels. Also, the addition of
500 ul/10 ml of OPP decreased the protein level of APP expression to the level at which
the WT control APP levels were measured at. This data shows that OPP may play a vital
role in directly decreasing the protein expression levels of APP, so much so, that it may
bring them back within normal levels.
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Other studies have also shown that antioxidants can decrease APP levels. In
2005, researchers used APP transgenic mice to examine the capabilities of certain
antioxidant enzymes. They discovered that the overexpression of APP caused a
reduction in the levels of the antioxidant enzymes. Also, they antioxidants were found to
be directly protective against APP toxicity (25).
Western blot analysis was also used to look at the differences in the COX-2
protein expression levels among the various OPP concentrations. After the data was
collected and graphed, OPP was found to produce a decrease in COX-2 protein levels of
expression. The FAD control band density was measured at approximately 20 INT/mm2
while all other samples of FAD that were incubated with OPP produced a band density
measured well below 5 INT/mm2. As in the APP results, the FAD samples containing
300 ul/10 ml and 500 ul/10 ml of OPP, had COX-2 levels reduced to a level close to that
of the WT control. In addition, the FAD control band density was approximately 20 times
greater then the WT control. This showed that the FAD control contained a much higher
level of COX-2.
Additional studies have found that the FAD model had higher levels of COX-2
and that the use of antioxidants decreased those levels. Hwang et al. found that
according to their western blot data, the COX-2 protein levels were 1.5 to 2 folds higher
in the brains of transgenic mice with presenilin 2 protein mutations when compared to
the control mouse. They were also able to link the location of the COX-2 immunopositive
neuronal cells to the same staining pattern as the Aβ-42 fragments (9). More similarly to
this study, in Aβ neuronal cells it was found that there were higher levels of COX-2 when
compared to the control. These cells also had a higher rate of apoptosis (22). Lastly, in
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2008, it was discovered that the tocotrienol- rich fraction of palm oil increased antiinflammatory activity by inhibiting the expression of COX-2 in monocytic cells. It was
discovered that the antioxidants suppressed the release of prostaglandin E2 resulting in
the downregulation of COX-2 (35).
The final western blot analysis conducted was completed in order to determine if
OPP could decrease the PARP protein expression levels. As expected from the previous
data, the addition of OPP dramatically decreased the levels of PARP in the FAD
samples. The FAD control was measured to have a band density of approximately 4
INT/mm2. With the addition of just 100 ul/10 ml of OPP, the PARP expression levels
decreased to such that the FAD 150 ul/10 ml sample band density was measured to only
be approximately 0.8 INT/mm2. All samples, except for the FAD control, had a band
density measurement of less than 1 INT/mm2.
The decrease in PARP levels with the addition of an antioxidant such as OPP is
supported by other previously conducted experiments. One study showed that a
tocotrienol rich fraction of palm oil had an inhibitory effect on the activation of NF-κB in
monocytic cells. This was shown by using the western blot analysis as well (35). In 2009,
a study conducted discovered that certain naturally occurring polyphenols such as
curcumin, prevented DNA damage and PARP-1 activation. They also took the
experiment one step further and showed that because of the inhibition of the PARP-1
activation, cells maintained their NAD+ pools ultimately preventing cell apoptosis (1).
APP, COX-2, and PARP protein expression levels decreased after OPP was
added. This shows that OPP may in fact positively affect the inflammatory pathway and
the APP levels. This is important due to APP being directly cleaved and producing Aβ
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plaques, and also because the inflammatory pathway plays such a crucial role in
oxidative stress and apoptosis in AD individuals. Although this data proves to be in the
right direction of OPP possibly decreasing certain inflammatory biomarkers associated
with AD, this study took one step further to try and determine if the cells were affected at
the mRNA level. This was accomplished by carrying out real time polymerase chain
reaction (PCR).
Real time PCR was the last experiment conducted in this study. For this
experiment, COX-2 and APP were examined. Once the protein was extracted and the
cDNA created, the data was collected and converted into a fold change graph. Looking
at the mRNA expression levels for APP in FAD cells, it was determined that due to the
fold increase being less than 1, there was no statistical significance between the control
and samples containing OPP. This may be due to the OPP not affecting the cells at the
mRNA level. This idea was further investigated by looking at the mRNA level of APP
expression in WT cells. Here it was discovered that there was a statistically significant
fold difference when comparing WT control and WT 150 to WT 300 and WT 600 ul/10 ml
samples.
The real time PCR data for the expression of COX-2 at the mRNA level also
showed a difference between the FAD and WT cells. FAD cells containing an OPP
concentration of 150 ul/10 ml was determined to be statistically significant from the FAD
control and other samples containing OPP. It had the highest level of COX-2 expression.
This data does not coincide with the information obtained from the western blot analysis.
Since it was the only sample to have been significantly different, there may have been
contamination to that sample; therefore, this assay needs to be revisited. The fold
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change graph for COX-2 expression in WT cells is similar to the graph for APP
expression. The WT control and WT 150 ul/10 ml sample was calculated to be
statistically significant from the WT 300 ul/10 ml sample. The control and 150 ul/10 ml
samples were also determined to be statistically significant from the WT 600 ul/10 ml
sample. In addition, the WT 300 ul/10 ml sample was statistically significant from the WT
600 ul/10 ml sample.
The variations in this data do not allow this study to accept or reject the idea that
OPP affects the cells at the mRNA level. The WT samples for COX-2 and APP
expression seem to show that the addition of OPP does in fact decrease the expression
levels of these biomarkers. The inconsistency is present when looking at the data for the
FAD cells. The expression levels of COX-2 and APP were expected to decrease once
OPP was added. For COX-2 expression, the FAD 150 ul/10 ml sample had the highest,
while for APP expression there was no differences between any of the FAD samples.
Although this data does show that the OPP decreased COX-2 and APP in WT cells, the
decrease should have been more prevalent and noticeable in the FAD cells. For this
reason, this experiment was not able to determine if OPP affects the cells at the mRNA
level.
Throughout the duration of this study there were many positive discoveries;
however, certain improvements could have been made in order to make these findings
more beneficial. First, a more appropriate cell line could have been chosen to use. The
B103 rat neuroblastoma cells were ideal for this study based on their ability to maintain
the cDNA mutant construct throughout multiple passages and also due to their extensive
use in AD research. However, the problem is that in AD, you want to preserve the
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neuronal cells while decreasing the inflammation and the number of Aβ plaques. A more
appropriate cell line would allow for biomarkers to be evaluated without having some
measurements recorded based on cell death, such as in the MTS assay.
In addition to possibly using a more appropriate cell line, the results from the ThT
binding assay should have been confirmed using the Congo red test. According to
recent experiments, polyphenols contain aromatic ring structures that are connected by
conjugated systems. This characteristic creates strong electronic transitions ultimately
making them intrinsically fluorescent. This may make the ThT binding assay unsuitable
for evaluating the effects of phenolics compounds such as OPP (8). Even though a
control was used in attempt to accommodate for that, the results for the inhibition of
formation assay were inconclusive and the results for the destabilization assay were
relative to 1; therefore, the results should have been confirmed using a different type of
experiment such as the Congo red test.
Lastly, the real time PCR should have been further optimized. These results did
not coincide with previous studies or with the data obtained in this study. According to
previous research, OPP can in fact alter certain gene expressions. For example, it has
been found to alter the expression of many genes on the spleen, liver, and heart (12).
With data showing OPP altering gene expression in certain tissues, real time PCR needs
to be further optimized and re-done in order to be sure of the data produced in this
study.
Despite certain setbacks, this study has provided more knowledge about how the
antioxidant, OPP, may aid in the decrease of inflammatory responses in AD individuals.
However, this study is not alone at looking into the effects antioxidants may have on AD
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as well as other similar diseases. For example, AD and Down syndrome are two
diseases that have neuronal cell death that is possibly caused by oxidative stress. In
recent Down syndrome cases, antioxidants have been found to delay premature
apoptotic death in neuronal cells (20). Also, recent studies have shown that when
patients with moderate AD are given antioxidants such as vitamin E and monoamine
oxidase B, they were found to deteriorate at a slower rate when compared to the
placebo group. In addition to this study, it was discovered that menopausal women
undergoing estrogen replacement therapy have a reduced risk of AD. This is thought to
be due to women receiving antioxidants that are estrogen derivatives. These results
relate back to the idea that as an individual ages, their antioxidant defense system
increases; however, their ROS formation also increases ultimately exceeding the
antioxidant capabilities and increasing oxidative stress (20). Based on this study and
previous ones, OPP may play an important role in decreasing APP, COX-2 and PARP
expressions at the protein level; therefore, its capabilities need to further evaluated.
Since OPP did show some antioxidant capabilities against AD characteristics, the
next step would be to take this study into the animal model. A recent study by Cole et al.
showed that non-steroidal anti-inflammatory drugs (NSAIDs) decreased the risk for AD
in the animal model. This was due to a significant suppression of inflammation. The
problem with using NSAIDs is that some also inhibit the activation of COX-1. Not having
COX-1 activated can lead to gastrointestinal, liver, and kidney toxicity (14). For these
reasons, a naturally occurring antioxidant such as OPP would be an excellent alternative
for AD patients.
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There have been many promising studies with OPP and other antioxidants in the
animal model representing AD. For example, curcumin has been discovered to suppress
specific inflammatory cytokines, reduce oxidative stress, and decrease the formation of
Aβ plaques. This was shown in the animal model and because of that it also provided
information relating to memory deficit. Using the Morris water maze, researchers found
that the animals who received curcumin in their diet showed lower Aβ induced memory
deficit when compared to the control mice (14). OPP has also been shown to act an antiinflammatory agent in the animal model. OPP promoted anti-inflammatory cytokine IL-13
and decreased the pro-inflammatory cytokine IL-12 (13). Theses studies show that
antioxidants, including OPP, can be used in the animal model to provide more
information on diseases such as AD.
Based on experiments such as the ones stated above and the one conducted
within this thesis, the next step to be taken would be to continue experiments such as
these in the animal model. There has been a lot of positive data and information
obtained from previous AD animal model studies; however, additional information is
needed. The etiology of non-familial AD is one important aspect that needs to better
understood. FAD has well known causes making the models easy to create, but with
only 1% of the population having FAD, non-familial AD needs to be examined and
researched more closely. Also, OPP has been found to not be toxic in the animal model
(12). This allows the optimal concentration to be further evaluated before pursuing
additional clinical studies.
As the baby boomer population continues to increase, AD needs to become
better understood. This study was completed as one small part in the ever expanding
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exploration of AD. With additional research, it is the hope of this study to find a natural
antioxidant such as OPP to help better the lives of AD individuals. Using OPP in the
animal model will hopefully provide more information and lead to additional discoveries
for the diagnosis, treatment, and hopefully some day the cure for AD.
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Alzheimer’s disease (AD) affects approximately 35.6 million people in the world
today (35). It is expected that by year 2050, an individual will develop AD every 33
seconds (8). Unfortunately, the etiology is not well known. Familial Alzheimer’s disease
(FAD) occurs due to specific genetic mutations, making it possible to replicate them in
cells. Using B103 rat neuroblastoma cells transfected with a cDNA construct, wild type
cells and FAD mutant cells were used in this research.
Natural ingredients such as oil palm phenolics (OPP) contain antioxidants. After
finding the optimal experimental parameters, OPP was found to aid in the destabilization
of Aβ plaques and also decrease the protein expression levels of amyloid precursor
protein (APP), and the inflammatory biomarkers poly (ADP-ribose) polymerase (PARP)
and cyclooxygenase-2 (COX-2). This research is one small step in better understanding
AD and how using ingredients such as OPP may help in one day developing a treatment
for this debilitating disease.
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